-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
1/170
!"#
$%&'&$(% *+($"&$# ,-&.#%&'#/
*012134563 738 "01749134 6:
!136;< "=069>619>6?5
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
2/170
!"#"$%$&" () *&"$&"
!"#$# &'()#*(+#$ ,-# .#,+/ /0 1# , &'()# 20- 3*(+(3,* 4-,3/(3#5 1,$#) 0+ /"# 1#$/
,6,(*,1*# #6()#+3# ,/ /"# /(.# 02 )#6#*04.#+/7 8)"#-#+3# /0 /"#$# &'()#*(+#$
.,9 +0/ +#3#$$,-(*9 #+$'-# /"# 1#$/ 0'/30.# (+ #6#-9 3,$#7 :6#-9 "#,*/" 3,-#
4-06()#- ($ -#$40+$(1*# 20- /"# .,+,.#+/ 04/(0+$ ,6,(*,1*# *03,**97
+$,*$- () ".$ /0*1$2*&$!
!"#$# &'()#*(+#$ ;#-# ($$'#) (+ ? ,+) ;(** 1# -#6(#;#) (+ @ 0- $00+#- (2
+#; #6()#+3# 1#30.#$ ,6,(*,1*#7
:*#3/-0+(3 6#-$(0+ ,6,(*,1*# 0+ /"# 20**0;(+& ;#1$(/#A
"//4ABB;;;7",#.,/0*0&970-&7.9
1*!32(!0+$ !"#"$%$&"
!"# 4,+#* .#.1#-$ ",) 30.4*#/#) )($3*0$'-# 20-.$7 C0+# "#*) $",-#$ (+
4",-.,3#'/(3,* 2(-.$ 0- ,3/#) ,$ 30+$'*/,+/$ /0 $'3" 2(-.$ D)#/,(*$ ,-# ,6,(*,1*#
'40+ -#E'#$/ 2-0. /"# FGH I#3-#/,-(,/J7
!(0+3$! () )0&1*&/
!"# )#6#*04.#+/ 02 /"# FGH 0+ G-#6#+/(0+ ,+) !-#,/.#+/ 02 K#+0'$!"-0.10#.10*($. ;,$ $'440-/#) 6(, '+-#$/-(3/#) #)'3,/(0+,* &-,+/ 2-0. L,9#-
M#,*/"3,-# G",-.,3#'/(3,*$7 !"# 2'+)(+& 10)9 ",$ +0/ (+2*'#+3#) /"#
)#6#*04.#+/ 02 /"# &'()#*(+#$7
8'&'$/ ?
N O(+($/-9 02 M#,*/" O,*,9$(,
=>
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
3/170=< 20- 2'-/"#-)#/,(*$7
!"#$# &'()#*(+#$ ",6# 1##+ 4-#$#+/#) /0 /"# !#3"+(3,* 8)6($0-9 F0..(//## 20-F*(+(3,* G-,3/(3# H'()#*(+#$ ,+) /"# M#,*/" !#3"+0*0&9 8$$#$$.#+/ ,+) F*(+(3,*G-,3/(3# H'()#*(+#$ F0'+3(*5 O(+($/-9 02 M#,*/" O,*,9$(, 20- -#6(#; ,+) ,44-06,*7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
4/170=?
(56$3"*,$!/$&$+#2 (56$3"*,$!!0 4-06()# #6()#+3#]1,$#) &'(),+3# (+ /"# .,+,.#+/ 02 6#+0'$/"-0.10#.10*($.7
!4$3*)*3 (56$3"*,$!
!!0 4-06()# &'(),+3# (+ 4-#6#+/(+& 6#+0'$ /"-0.10#.10*($.!!0 4-06()# &'(),+3# (+ )(,&+0$(+& 6#+0'$ /"-0.10#.10*($.!!0 4-06()# &'(),+3# (+ /-#,/(+& 6#+0'$ /"-0.10#.10*($.!!0 4-06()# &'(),+3# (+ ,+/(30,&'*,/(0+ ,+) .0+(/0-(+&!!0 4-06()# &'(),+3# (+ .,+,&(+& 1*##)(+& 30.4*(3,/(0+$ 02 ,+/(30,&'*,+/$!!0 4-06()# &'(),+3# (+ .,+,&(+& K!: (+ $4#3(,* 404'*,/(0+$!!0 4-06()# &'(),+3# (+ .,+,&(+& /"-0.10$($ (+ '+'$',* $(/#$!!0 4-06()# &'(),+3# (+ 4#-(04#-,/(6# .,+,.#+/ 02 ,+/(30,&'*,/(0+
!!0 4-06()# &'(),+3# (+ #$/,1*($"(+& , O#)(3,/(0+ !"#-,49 8)"#-#+3# F*(+(3 ] [,-2,-(+DO!8F][J
*7 89 :;7 7?=@78A= ;B 7?
"#+/$" /+(04J0!$+8** "#,*/" 3,-# 4-02#$$(0+,*$
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
5/170=^
/0*1$2*&$! 1$,$2(4%$&" /+(04
F",(-4#-$0+4G;B=99;G 1G #>EDF +K9EDF +K
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
6/170=a
+$,*$- 3(%%*""$$!"# )-,2/ 02 /"#$# &'()#*(+#$ ,-# -#6(#;#) 19 , 4,+#* 02 (+)#4#+)#+/ #X4#-/-#2#-##$ 2-0. 10/" 4'1*(3 ,+) 4-(6,/# $#3/0-$5 ;"0 ;#-# ,$Z#) /0 30..#+/4-(.,-(*9 0+ /"# 30.4-#"#+$(6#+#$$ ,+) ,33'-,39 02 (+/#-4-#/,/(0+ 02 /"##6()#+3# $'440-/(+& /"# -#30..#+),/(0+$ (+ /"# &'()#*(+#$7
F",(-.,+1G 3
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
7/170=d
1G !
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
8/170
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
9/170=Y
" O#/,10*(35 #+)03-(+# 0- -#$4(-,/0-9 4,/"0*0&(#$!
" 83'/# (+2#3/(0'$ )($#,$#!
" S+2*,..,/0-9 30+)(/(0+$!
" I(3Z*# 3#** )($#,$#!
" !",*,$$,#.(, !
! K,-(30$# 6#(+$ ;(/" 4"*#1(/($!
! 83/(6# 1*##)(+&!
! 83E'(-#) 1*##)(+& )($0-)#-$ D$'3" ,$ ,3'/# *(6#- 2,(*'-#J !
! F0+3'--#+/ '$# 02 ,+/(30,&'*,+/$ D#7&7 ;,-2,-(+ ;(/" SCV f
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
10/170=c
^X %=7^ ] >a ..M&
! :+30'-, 4,/(#+/$ /0 ;#,- /"#(- $/03Z(+&$ ),9 ,+) +(&"/ '+/(* /"#9 +0*0+- ",6# $(&+(2(3,+/*9 -#)'3#) .01(*(/9
! V#.06# $/03Z(+&$ ),(*9 20- "9&(#+# 4'-40$#$ ,+) /0 (+$4#3/ $Z(+
! :+30'-, 4,/(#+/ /0 '$# 200/ )#6(3#$ 10/" (+ 1#) ,+) ;"#+ $(//(+& (+, 3",(-
);;7 8LVDF9= E=A8@=9
! :+30'-, 4,/(#+/ /0 '$# SGF )#6(3#$ 20- ,$ .'3" /(.# ,$ 40$$(1*# 10/"(+ 1#) ,+) ;"#+ $(//(+& (+ , 3",(-
*:7=GL877=:7 V:=DLK78@ @;LVG=998;: E=A8@=9 `7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
11/170>=
! F"00$# ,+9 0+# 02A
" R0; .0*#3'*,- ;#(&"/ "#4,-(+ IF !
" b0+),4,-(+'X $0)('. IF !
" V(6,-0X,1,+ GP D,/ 4-#$#+/5 *(3#+$#) 20- !MV ,+) !`VJ !
" U,1(&,/-,+ #/#X(*,/# GP D,/ 4-#$#+/5 *(3#+$#) 20- !MV ,+) !`VJ!
" T+2-,3/(0+,/#) "#4,-(+ IF !
! F"00$# #(/"#-A
" :+0X,4,-(+ ! :+0X,4,-(+ ^= .& ),(*9 0- :+0X,4,-(+ K:
" U,1(&,/-,+ ! I/,-/(+& )0$# ,/ >>= .& D> ] ^ "0'-$ ,2/#- $'--9J 20**0;#) 198CK7GK: =7=W8FK7=
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
12/170>>
! F"00$# TbM 20- 4,/(#+/$ ;(/" $#6#-# -#+,* (.4,(-.#+/
D#HbV h>a .RB.(+B>7@?B.== ),9$ ,+) ,-# -#3#(6(+& ,+9/94# 02 "#4,-(+ $"0'*) ",6# , 4*,/#*#/ 30'+/ )#/#-.(+#)
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
13/170> ] ^ "0'-$ ,2/#- $'--9!
" F0+/(+'# 4",-.,30*0&(3,* K!: 4-04"9*,X($ 20- ?a ),9$
$F=@78A= = "0'-$ ,2/#- $'--9!
U,1(&,/-,+ #/#X(*,/#A $/,-/(+& > ] ^ "0'-$ ,2/#- $'--9!
" F0+/(+'# 4",-.,30*0&(3,* K!: 4-04"9*,X($ 20- ?a ),9$
$F=@78A= O:== G=VFK@=L=:7
" I/,-/ .#3",+(3,* K!: 4-04"9*,X($ ,/ ,).($$(0+
" 8)) 4",-.,30*0&(3,* K!: 4-04"9*,X($7 F"00$# ,+9 0+# 02A
RO[MA $/,-/(+& ,/ ,).($$(0+5 $/044(+& >< "0'-$ 1#20-# $'--9 ,+)
-#$/,-/(+& d ] >< "0'-$ ,2/#- $'--9 !
b0+),4,-(+'XA $/,-/(+& d "0'-$ ,2/#- $'-&(3,* 3*0$'-#7 S/ ($ +0/
-#30..#+)#) 20- '$# 4-#]04#-,/(6#*9 20- 4,/(#+/$ '+)#-&0(+& "(4
2-,3/'-# $'--9 !
" F0+/(+'# 4",-.,30*0&(3,* K!: 4-04"9*,X($ 20- ?a ),9$
.8V BGK@7DG=
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
15/170>^
,K9@DFKG 9DGC=GM
! P22#- K!: 4-04"9*,X($ /0 4,/(#+/$ '+)#-&0(+& 6,$3'*,- $'--9 ;"0,-# +0/ ",6(+& 0/"#- ,+/(30,&'*,+/ /"#-,49 ,+) ,-# ,$$#$$#) /0 1# ,/(+3-#,$#) -($Z 02 K!:
! I/,-/ .#3",+(3,* K!: 4-04"9*,X($ ! 8)) 4",-.,30*0&(3,* K!: 4-04"9*,X($ 20- 4,/(#+/$ ;"0 ",6# ,
*0; -($Z 02 1*##)(+& ! F0+/(+'# 4",-.,30*0&(3,* K!: 4-04"9*,X($ '+/(* /"# 4,/(#+/ +0 *0+-
",$ $(&+(2(3,+/*9 -#)'3#) .01(*(/9
%K?;G 7GKDLK
! P22#- 30.1(+#) K!: 4-04"9*,X($ ;(/" .#3",+(3,* ,+)4",-.,30*0&(3,* .#/"0)$ /0 4,/(#+/$ ;(/" .,_0- /-,'.,
! V#&'*,-*9 -#,$$#$$ /"# 4,/(#+/e$ -($Z$ 02 K!: ,+) 1*##)(+& ! I/,-/ .#3",+(3,* K!: 4-04"9*,X($ ,/ ,).($$(0+ 0- ,$ #,-*9 ,$
3*(+(3,**9 40$$(1*# ! F0+/(+'# .#3",+(3,* K!: 4-04"9*,X($ '+/(* /"# 4,/(#+/ +0 *0+- ",$
$(&+(2(3,+/*9 -#)'3#) .01(*(/9 ! 8)) 4",-.,30*0&(3,* K!: 4-04"9*,X($ (2 /"# 1#+#2(/$ 02 -#)'3(+& /"#
-($Z 02 K!: 0'/;#(&"$ /"# -($Z 02 1*##)(+& ,+) /"# 1*##)(+& -($Z ",$1##+ #$/,1*($"#) ,$ *0;
! F0+/(+'# 4",-.,30*0&(3,* K!: 4-04"9*,X($ '+/(* /"# 4,/(#+/ +0 *0+-",$ $(&+(2(3,+/*9 -#)'3#) .01(*(/9
!V8:KF 8:?DGM
! P22#- 30.1(+#) K!: 4-04"9*,X($ ;(/" .#3",+(3,* ,+)4",-.,30*0&(3,* .#/"0)$ /0 4,/(#+/$ ;(/" $4(+,* (+_'-9
! V#&'*,-*9 -#,$$#$$ /"# 4,/(#+/e$ -($Z$ 02 K!: ,+) 1*##)(+& ! I/,-/ .#3",+(3,* K!: 4-04"9*,X($ ,/ ,).($$(0+ 0- ,$ #,-*9 ,$
3*(+(3,**9 40$$(1*# ! F0+/(+'# .#3",+(3,* K!: 4-04"9*,X($ '+/(* /"# 4,/(#+/ +0 *0+- ",$
$(&+(2(3,+/*9 -#)'3#) .01(*(/9 ! 8)) 4",-.,30*0&(3,* K!: 4-04"9*,X($ (2 /"# 1#+#2(/$ 02 -#)'3(+& /"#
-($Z 02 K!: 0'/;#(&"$ /"# -($Z 02 1*##)(+& ,+) /"# 1*##)(+& -($Z ",$1##+ #$/,1*($"#) ,$ *0;
! F0+/(+'# 4",-.,30*0&(3,* K!: 4-04"9*,X($ '+/(* /"# 4,/(#+/ +0 *0+-",$ $(&+(2(3,+/*9 -#)'3#) .01(*(/9
2;R=G F8L> VFK97=G @K979
! F0+$()#- 4",-.,30*0&(3,* K!: 4-04"9*,X($ /0 4,/(#+/$ ;(/" *0;#- *(.1
4*,$/#- 3,$/$ ,2/#- #6,*',/(+& /"# -($Z$ ,+) 1#+#2(/$ 1,$#) 0+ 3*(+(3,*)($3'$$(0+ ;(/" /"# 4,/(#+/ ! P22#- 4",-.,30*0&(3,* K!: 4-04"9*,X($ '+/(* *0;#- *(.1 4*,$/#- 3,$/ -#.06,*
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
16/170>a
4G=C:K:@M K:E DV 7; ^ R==O9 V;97_VKG7DL
! 8** ;0.#+ $"0'*) 1# ,$$#$$#) ,/ 100Z(+& ,+) ,2/#- )#*(6#-9 ,+)$/-,/(2(#) (+/0 -($Z &-0'4$ ,330-)(+& /0 -($Z 2,3/0-$ ,+) 022#-#)/"-0.104-04"9*,X($ ;(/" RO[M ;"#-# ,44-04-(,/#
! !"($ ,$$#$$.#+/ $"0'*) 1# -#4#,/#) (2 /"# ;0.,+ ($ ,).(//#) /0 /"#"0$4(/,* 20- ,+9 -#,$0+ 0- )#6#*04$ 0/"#- (+/#-3'--#+/ 4-01*#.$ )'-(+&/"# ,+/#+,/,* ,+) 40$/4,-/'. 4#-(0)
3G878@KF @KG=
! 8$$#$$ ,** 4,/(#+/$ 0+ ,).($$(0+ /0 /"# 3-(/(3,* 3,-# '+(/ 20- /"#(- -($Z$02 K!: ,+) 1*##)(+&
! V#,$$#$$ 4,/(#+/$e -($Z$ 02 K!: ,+) 1*##)(+& ),(*9 ,+) .0-#2-#E'#+/*9 (2 /"#(- 3*(+(3,* 30+)(/(0+ ($ 3",+&(+& -,4()*9
! P22#- K!: 4-04"9*,X($ /0 4,/(#+/$ ,).(//#) /0 /"# 3-(/(3,* 3,-# '+(/,330-)(+& /0 /"# -#,$0+ 20- ,).($$(0+5 /,Z(+& (+/0 ,330'+/A
8+9 4*,++#) (+/#-6#+/(0+$ !"# '$# 02 0/"#- /"#-,4(#$ /",/ .,9 (+3-#,$# /"# -($Z 02
30.4*(3,/(0+$
0:BGK@78;:K7=E @D7K:=;D9a
! [,(/ ,/ *#,$/ ^ "0'-$ ,2/#- , )0$# 1#20-# 1*03Z 0- 3,/"#/#- -#.06,*
! [,(/ ,/ *#,$/ > "0'- 1#20-# )0$(+& ,2/#- 4-03#)'-# D3,/"#/#- (+$#-/(0+
0- ;(/")-,;,*J
0:BGK@78;:K7=E
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
17/170>d
! I/,-/ (+2'$(0+ f> "0'- ,2/#- 1*03Z ! V#.06# #4()'-,* 3,/"#/#- +0 $00+#- /",+ < ] ^ "0'-$ ,2/#-
)($30+/(+',/(0+ 02 (+2'$(0+
2;R %;F=@DFKG -=8C< "0'-$ ,2/#- , 4-04"9*,3/(3 )0$# 1#20-# 1*03Z ! [,(/ ,/ *#,$/
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
18/170>@
! L#20-# $/,-/(+& K!: 4-04"9*,X($5 022#- 4,/(#+/$ ,+) /"#(- 2,.(*(#$6#-1,* ,+) ;-(//#+ (+20-.,/(0+ 0+A
!"# -($Z$ ,+) 40$$(1*# 30+$#E'#+3#$ 02 K!: !"# (.40-/,+3# 02 K!: 4-04"9*,X($ ,+) (/$ 40$$(1*# $()#]#22#3/$ !"# 30--#3/ '$# 02 K!: 4-04"9*,X($
M0; 4,/(#+/$ 3,+ -#)'3# /"# -($Z 02 K!: DZ##4(+& ;#** "9)-,/#),+) .01(*(g(+& #,-*9J
! 8$ 4,-/ 02 /"# )($3",- 4*,+5 022#- 4,/(#+/$ ,+) /"#(- 2,.(*(#$ 0-
3,-#-$ 6#-1,* ,+) ;-(//#+ (+20-.,/(0+ 0+A
" !"# $(&+$ ,+) $9.4/0.$ 02 UK! ,+) G:
"!"# -#30..#+)#) )'-,/(0+ 02 '$# 02 K!: 4-04"9*,X($ ,/ "0.# D(2
)($3",-) ;(/" 4-04"9*,X($J ":+$'-# /",/ 4,/(#+/$ ;"0 ,-# )($3",-) ;(/" 4",-.,30*0&(3,* 0-
.#3",+(3,* K!: 4-04"9*,X($ ,-# ,1*# /0 '$# (/ 30--#3/*9
"`+0; ;"0 /0 30+/,3/ (2 UK!5 G: 0- ,)6#-$# #6#+/$ ,-# $'$4#3/#)
UUX 189@
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
19/170>Y
4#".-#P YH %#/$%$&" () ,"$Y
&KL= ;B #99=99;GH 1K7=H
18KC:;989 K:E "G=K7L=:7 ;B ,=:;D9
";=L>;F89L
%8:897GM ;B .=KF7c
1," P=9 &; 4$ P=9 &;
83/(6# 3,+3#- 0- 3,+3#-
;(/"(+ d .0+/"$
> = F*(+(3,* $(&+$ Q $9.4/0.$
02 UK! D.(+(.'. 02 *#&$;#**(+& ,+) 4,(+ ;(/"
4,*4,/(0+ 02 /"# )##4 6#(+$
? =
G,-,*9$($ 0- -#3#+/ *#&
4*,$/#-
> = 8+ ,*/#-+,/(6# )(,&+0$($ ($
*#$$ *(Z#*9 /",+ G:
? =
L#)-())#+ f? ),9$
0- .,_0- $'--9 h> = M#,-/ -,/# f>== 1#,/$B.(+ >7a =
!#+)#-+#$$ ,*0+& )##4
6#+0'$ $9$/#.
> = S..01(*(g,/(0+ f? ),9$ 0-
$'--9 (+ /"# 4-#6(0'$ ^
;##Z$
>7a =
G(//(+& #)#.,
D$9.4/0.,/(3 *#&J
> = O,*(&+,+39 D0+ /-#,/.#+/j
/-#,/#) (+ /"# *,$/ d
.0+/"$j 0- 4,**(,/(6#
> =
F,*2 $;#**(+& f? 3. /",+,$9.4/0.,/(3 *#&
> = M,#.04/9$($ > =
F0**,/#-,* $'4#-2(3(,*
6#(+$
> =
G-#6(0'$*9 )03'.#+/#)
UK!
> =
8*/#-+,/(6# )(,&+0$($
.0-# *(Z#*9
]< =
:+/(-# *#& $;0**#+ > = G-#6(0'$ UK!BG: >7a =
1," F8O=FM !Y 4$ F8O=FM g[
1," D:F8O=FM hU 4$ D:F8O=FM "#
[X 3F8:8@KF 4G;>K>8F87M
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
21/170
\X .897;GM
bX 5F;;E 7=979
M($/0-9 02 4-#$#+/ (**+#$$
G,$/ .#)(3,* "($/0-9
8**#-&(#$U-'& "($/0-9
^X +89O )K@7;G9
! P1#$(/9!
! I.0Z(+& !
! O,*(&+,+39
!
! 8+/(]4"0$4"0*(4() $9+)-0.#!
! PFG!
! MV!!
! G-#&+,+39 !
! G0$/]4,-/'. D;(/"(+ >< ;##Z$J!
! G-#6(0'$ K!: !
! b,.(*9 "B0 K!: !
! V#3#+/ *#& /-,'., 0- 4*,$/#-!
! V#3#+/ ,1)0.(+,* 0- 4#*6(3 $'--9!! L#)-())#+ f? ),9$ !
! C#4"-0/(3 $9+)-0.#!
! I(3Z*# 3#** )($#,$#!
! !",*,$$,#.(, !
! S+2*,..,/0-9 10;#* )($#,$#!
bLF
F0,&'*,/(0+ 4-02(*#
V#+,* 4-02(*#
R(6#- 2'+3/(0+
T-(+,*9$($
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
22/170
I'&$/ -#4#,/ $3,+ (+ @ ),9$U,/#A
L#*0; Z+## 8106# Z+##
G-03##) /0 /-#,/.#+/
V#4#,/ $3,+ +#&,/(6#
U($3",- 4,/(#+/ /0 M#,*/" F*(+(3
cX 1," F8O=FM
V#E'#$/ 20- U044*#- T*/-,$0'+) U,/# 02 TIA
UK! 30+2(-.#) UK! +0/ 30+2(-.#)
eX (7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
23/170 .&BZ& /;(3# ),(*9!
"b0+),4,-(+'X )0$# ($ @7a .& ),(*9
Da .& (2 ha= Z&j >= .& (2 f>== Z&J!
! I/,-/ K`8 (7#7 ;,-2,-(+ ,/ a .& ),(*9 ;(/"(+
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
24/170
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
25/170
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
26/170
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
27/170]d S+/-0)'3/(0+ d?
d7< !"-0.10#.10*(3 -($Z d?]d^
d7? L*##)(+& -($Z (+ $'--9 d^]da
d7^ O,+,&(+& ,+/(30,&'*,/(0+ (+ $'--9 da]dY
bXf %#/$%$&" () (,$+_#&"*3(#/02#"*(& ^e_b\ @7> [,-2,-(+ ,+) 1*##)(+& dc
@7< [,-2,-(+ -#6#-$,* dc]@=
@7? O,+,.#+/ 02 06#-];,-2,-(+($,/(0+ @=]@>
@7^ I4#3(2(3 3*(+(3,* $3#+,-(0$ @
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
28/170 !"# #*)#-*95 -#+,* (.4,(-.#+/ ,+) 01#$(/9 Y@]YY
c7< 8+/(30,&'*,/(0+ 20- #$/,1*($"#) K!: (+ $/-0Z# 4,/(#+/$ YY
c7? 8+/(/"-0.10/(3 /"#-,49 (+ 3"(*)-#+ YY]cd
c7^ b#-/(*(/9 /-#,/.#+/ ,+) K!: cd]cY
c7a M0-.0+,* 30+/-,3#4/(0+ ,+) K!: cc]>=> c7d K!: ,+) 3,+3#- >==?
c7@ !"-0.10$($ (+ '+'$',* $(/#$ >=^]>=a
UfXf %$1*3#"*(& ".$+#4P #1.$+$&3$ 32*&*3_-#+)#+*& `%"#3_-a Uf^_UUY >=7> S+/-0)'3/(0+ >=d
>=7< C,/(0+,* &'(),+3# ,+) ,))(/(0+,* -#$0'-3#$ >=d
>=7? P1_#3/(6#$ >=@
>=7^ V#$40+$(1(*(/(#$ 02 /"# 3*(+(3,* 4",-.,3($/ (+]3",- >=@ ]>=Y
>=7a O,+40;#- -#E'(-#.#+/ >=Y
>=7d 8440(+/.#+/ >=Y
>=7@ [0-Z 4-03#)'-#$ >=Y >=7Y G,/(#+/ $#*#3/(0+ >=Y ]>=c
>=7c SCV /#$/(+& >=c
>=7>= G,/(#+/ 30'+$#*(+& >=c ]>>=
>=7>> O0+(/0-(+& ,+) #6,*',/(0+ >>=
>=7>< U0$, ,)_'$/.#+/ >>>
>=7>? U($4#+$(+& >>>
>=7>^ O($$#) ,440(+/.#+/$ >>=7>a U03'.#+/,/(0+ >>=7>d \',*(/9 ,$$'-,+3# >> [,-2,-(+ U0$, 8)_'$/.#+/ >>?]>>@
844#+)(X < O!8F [,-2,-(+ F*(+(3 [0-Z2*0; >>Y
844#+)(X ? O!8F ] [,-2,-(+A V#2#--,* b0-. DO!8F][ bB>J >>c]>??
844#+)(X Y [,-2,-(+ R,1#* >?^
844#+)(X c [,-2,-(+ U0$(+& C0/# >?a
844#+)(X >= O($$#) 8440(+/.#+/ V#30-) >?d
844#+)(X >> O,+,.#+/ P2 [,-2,-(+ 8+/(30,&'*,/(0+ S+ F"(*)-#+ DTOOF H'()#*(+#$ ?J >?@]>^^
844#+)(X >< R#6#* P2 :6()#+3# >^a844#+)(X >? F*(+(3,* \'#$/(0+$ >^d]>^@
+$)$+$&3$! U[c_U^c
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
29/170Y
M0$4(/,*],3E'(-#) K!: (+ 8$(, ($ (+3-#,$(+&7>^]>dG'*.0+,-9 #.10*($. ,330'+/$ 20-'4 /0 dn 02 "0$4(/,* )#,/"$7a 83E'(-#) 2,3/0-$ $'3" ,$ (..01(*($,/(0+5 ,3/(6#3,+3#-5 (+2#3/(0+$5 ,)6,+3(+& , "#,-/ )($#,$#$ ,+) .,_0- $'--(#$ ,-#,$$03(,/#) ;(/" ,+ (+3-#,$# -($Z 02 K!:7>@
K#+0'$ /"-0.10#.10*($. (+ 01$/#/-(3$ ($ ,*$0 0+ /"# -($# (+ /"# :,$/ )'# /0 $#6#-,*2,3/0-$ $'3" ,$ (+3-#,$(+& .,/#-+,* , 01#$(/95 -($(+& /-#+) 20- 3,#$,-#,+)#*(6#-(#$5 .'*/(4*# 4-#&+,+3(#$ ,+) *0; -,/# 20- /"-0.104-04"9*,X($7P1$/#/-(3
K!: ($ +0; /"# *#,)(+& 3,'$# 02 .,/#-+,* )#,/" (+ O,*,9$(,7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
30/170
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
31/170?=
"0+#2 .*!"(+P () ,"$
! O0$/ UK! 1#&(+ (+ /"# 3,*27 S+ 4-#&+,+39 (/ 1#&(+$ (+ /"# 4-0X(.,* ,+)
4#*6(3 6#(+$
! !"# -($Z 2,3/0-$ 20- K!: (+2*'#+3# ,/ *#,$/ 0+# 02 K(-3"0;e$ /-(,)A 1*00)
30,&'*,1(*(/95 6#$$#* (+/#&-(/9 ,+) 1*00) 2*0;! !"# -($Z 02 K!: ($ "(&"#$/ 20**0;(+& .,_0- 0-/"04#)(3 $'--9 ;"#-#
6#$$#* ),., ,+) (..01(*(/9 4*,9 , .,_0- -0*#
! !"# -($Z 02 $9.4/0.,/(3 K!: ($ "(&"#$/ ;(/"(+ < ;##Z$ 02 $'--9 ,+)
-#.,(+$ #*#6,/#) 20- , 2'-/"#- < /0 ? .0+/"$
! !"# -($Z 02 2,/,* G: ($ "(&"#$/ ;(/"(+ > ;##Z 02 $'--9
! b0**0;(+& /-#,/.#+/5 /"# -#$0*'/(0+ 02 UK! ($ $*0;#- /",+ 20- G: ;(/"
30.4*#/# -#$0*'/(0+ 1#(+& .0-# 30..0+ ;(/" G: /",+ (+ UK!5 ;"#-#
-#3,+,*($,/(0+ ($ 30..0+#-
! !"# -($Z 02 K!: -#3'--#+3# ($ "(&"#- (+ '+4-060Z#) /",+ (+ 4-060Z#)D-#3#+/ $'--9J K!:
! !"# -($Z 02 -#3'--#+3# -#.,(+$ #*#6,/#) ,2/#- , 2(-$/ #4($0)# 02 K!:
! 83/(6# 3,+3#- ,+) /"# ,+/(]4"0$4"0*(4() $9+)-0.# ,-# -($Z 2,3/0-$ 20-
K!: -#3'--#+3#
! !"# -($Z 02 .0-/,*(/9 ($ "(&"#- ;(/" -#3'--#+/ G: /",+ -#3'--#+/ UK!
! G0$/]/"-0.10/(3 $9+)-0.# ,+) 3"-0+(3 /"-0.10#.10*(3 4'*.0+,-9
"94#-/#+$(0+ ,-# 30.4*(3,/(0+$ 02 K!:
! G0$/]/"-0.10/(3 $9+)-0.# 033'-$ .0-# 2-#E'#+/*9 20**0;(+&
4-#&+,+39],$$03(,/#) K!: 1#3,'$# /"# 4-0X(.,* (*(0]2#.0-,* 6#(+$ ,-#
'$',**9 (+60*6#)
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
32/170?>
YXf ,"$ 4+(4.P2#T*!
YXU *&"+(103"*(&
K!: ($ ,+ (.40-/,+/ 3,'$# 02 )#,/" (+ "0$4(/,* 4,/(#+/$ ,+) /-#,/.#+/ 02 K!: ,+)
(/$ -#*,/#) *0+&]/#-. .0-1()(/(#$ ,-# ,$$03(,/#) ;(/" 30+$()#-,1*# 30$/ /0 /"# "#,*/"
$#-6(3#7 :220-/$ $"0'*) 1# .,)# /0 4-#6#+/ /"# 033'--#+3# 02 K!: 19 $/-,/(29(+&"0$4(/,*($#) 4,/(#+/$ ,330-)(+& /0 -($Z 3,/#&0-(#$ ,+) 022#-(+& /"-0.104-04"9*,X($
;"#+ ,44-04-(,/#7
YXY %$".(1! () 4+(4.P2#T*!YXYXU %=@
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
33/170?@ /0 "0'-$ ,**0;$ 0+3#]),(*9 )0$(+&7 S/ ($ #*(.(+,/#) '+3",+) (+
'-(+#j 1'/ (/$ #*(.(+,/(0+ ($ 4-0*0+) (+ 4,/(#+/$ ,) f@a 9#,-$ ,+) (+ /"0$#
;#(&"(+& ha=Z&7a@
b0+),4,-(+'X ",$ 1##+ $"0;+ /0 1# #22#3/(6# (+ 4-#6#+/(+& K!: (+ Z+## ,+) "(4
-#4*,3#.#+/ $'--(#$5 "(4 2-,3/'-# $'--(#$5 ,1)0.(+,* $'--(#$ ,+) ,3'/#
.#)(3,**9 (** 4,/(#+/$7 S/ 3,+ 1# '$#) ,$ ,+ ,*/#-+,/(6# /0 RO[M7 S/ ($ *(3#+$#) 20-
'$# 0'/$()# 4-#&+,+397 !"# 4-04"9*,3/(3 )0$# ($
YXYXYXZ 0:BGK@78;:K7=E .=VKG8:
T+2-,3/(0+,/#) "#4,-(+ ($ +0 *0+- /"# 4-#2#--#) 2(-$/ *(+# ,+/ ,$ (/ -#E'(-#$30.4*#X *,10-](+/#+$(6# ,).(+($/-,/(0+5 .0+(/0-(+& ,+) )0$# ,)_'$/.#+/7 O,_0-
1*##)(+& #6#+/$5 -($Z 02 MS!! ,+) ,$$03(,/#) 30$/$ 2,60'- 0/"#- +#;*9 ,6,(*,1*#
,+/$7d>
I'13'/,+#0'$ *0;])0$# TbM ,).(+($/#-#) (+ , )0$# 02 a=== ST #6#-9 >< "0'-$
,2/#- /"# $'--9 -#)'3#$ /"# -,/# 02 K!: (+ 4,/(#+/$ '+)#-&0(+& , .0)#-,/# -($Z
$'--97aa5ad M0;#6#-5 (/ ($ *#$$ #22#3/(6# /",+ ;,-2,-(+5 ,)_'$/#)])0$# TbM ,+)
RO[M ;"#+ '$#) ,$ 4-04"9*,X($ (+ #*#3/(6# "(4 $'--97 S+ #*#3/(6# "(4 $'--95 /"#
#22(3,39 02 TbM ($ #+",+3#) 19 ,)_'$/(+& /"# )0$#5 #7&7 ?a== ST Y]"0'-*95 $/,-/(+&
/;0 ),9$ 1#20-# $'--9 ,+) ,)_'$/(+& /"# )0$# /0 .,(+/,(+ /"# ,3/(6,/#) 4,-/(,*
/"-0.104*,$/(+ /(.# D8G!!J -,/(0 (+ /"# '44#- +0-.,* -,+aY5d=5d>
YXYXYX[ ,87KL8: N #:7KC;:8978)_'$/#)])0$# ;,-2,-(+5 "($/0-(3,**9 /"# 4-(.,-9 ,+/ '$#) 4#-(]04#-,/(6#*9 ,+)
30.4,-#) ;(/" .#3",+(3,* /"-0.104-04"9*,X($ 0- 4*,3#105 ;,$ #22#3/(6# (+
-#)'3(+& K!: ,+) (/$ 30+$#E'#+3#$7d
K!: 4-04"9*,X($ ;(/" ;,-2,-(+ 3,+ 1# 30..#+3#) 4-#]04#-,/(6#*9 D-($Z 02 .,_0-
1*##)(+& #6#+/J5 ,/ /"# /(.# 02 $'--9 0- ,/ /"# #,-*9 40$/]04#-,/(6# 4#-(0) D.,9 +0/4-#6#+/ $.,** 6#+0'$ /"-0.1( 20-.,/(0+ )'-(+& 0- $00+ ,2/#- $'--9 1#3,'$#
,+/(30,&'*,/(0+ #22#3/ ($ +0/ ,3"(#6#) '+/(* /"# /"(-) 0- 20'-/" 40$/]04#-,/(6# ),9J7 S2
$/,-/#) ,/ , *0; )0$# 1#20-# $'--95 (/ .,9 -#)'3# /"# -($Z 02 1*##)(+& 30.4,-#) /0
2'** ,+/(30,&'*,/(0+ ,/ /"# /(.# 02 $'--97dc
!"# ,)6,+/,$ ,-# (/$ #,$# 02 0-,* ,).(+($/-,/(0+ ,+) *0; 30$/7 !"# )($,)6,+/,$
(+3*')# )#*,9#) 0+$#/ 0+ ,3/(0+5 +,--0; /"#-,4#'/(3 -,+ )-'&])-'& (+/#-,3/(0+ ,+)
-#E'(-#.#+/ 20- ),(*9 .0+(/0-(+& 02 /"# SCV D/"# -#30..#+)#) /"#-,4#'/(3 -,+ ($
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
34/170??
YXYXYX\ (GKF 18G=@7 "8: *:87;G9U,1(&,/-,+ #/#X(*,/# ",$ 1##+ #6,*',/#) 20- K!: 4-04"9*,X($ (+ 4,/(#+/$ '+)#-&0(+&!MV ,+) !`V ,+) /"# -#$'*/$ $"0; /",/ (/ ($ +0+](+2#-(0- /0 RO[M ;(/" $(.(*,-1*##)(+& -,/#$7 U,1(&,/-,+ 3,+ 1# 30+$()#-#) ,+ ,*/#-+,/(6# /0 RO[M ,+)20+),4-(+'X 20- /"# 4-#6#+/(0+ 02 K!: 20**0;(+& !MV ,+) !`V $'--(#$7d=
!"# )0$# ($ >>= .& &(6#+ > /0 ^ "0'-$ 40$/]04#-,/(6#*9 ,+) 30+/(+'#) ;(/" , )0$# 025@?
YXYXYX^ (GKF 18G=@7 )K@7;G TK #:7KC;:8979J*:87;G9YXYXYX^XU +8AKG;WK>K:V(6,-0X,1,+ ",$ , -,4() 0+$#/ 02 ,3/(0+ 19 -#,3"(+& 4#,Z 30+3#+/-,/(0+ ,/ ?"0'-$7 L(0,6,(*,1(*(/9 -,+$ 1#/;##+ d= /0 Y=n ,2/#- 0-,* ,).(+($/-,/(0+7 S/ ($
.,(+*9 .#/,10*(g#) 6(, FmG?8^ ,+) #*(.(+,/#) 19 10/" /"# -#+,* ,+) 2#3,*B 1(*(,-9-0'/#$7 S/ ",$ ,+ #*(.(+,/(0+ ",*2]*(2# 1#/;##+ a /0 c "0'-$7ac
8 $(+&*# )0$# 02 -(6,-0X,1,+ 4-0)'3#$ 4",-.,30*0&(3 #22#3/$ /",/ 4#-$($/ 20- J ;(/" *0;]-($Z 4,/(#+/$",6(+& , =7?n -,/# 02 )#6#*04(+& $9.4/0.,/(3 K!: (+ c= ),9$ ,+) "(&" -($Z4,/(#+/$ ",6(+& ,+ >>n -,/# 02 )#6#*04(+& K!: ;(/"(+ c= ),9$7>!"# GGI $"0'*)+0/ 1# ,44*(#) /0 3-(/(3,**9 (** 4,/(#+/$7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
35/170?^
"K>F= YXZXUXUH 4KEDK +89O #99=99L=:7 %;E=F B;G %=E8@KF 4K78=:79b[
`+#% !@;G= ;B [ K:E K>;A= i
M#,-/ ,+)B0- -#$4(-,/0-9 2,(*'-# >
8OS 0- ($3"#.(3 $/-0Z# >
83'/# (+2#3/(0+ ,+)B0- -"#'.,/0*0&(3 )($0-)#- >
P1#$(/9 LOS f?=Z&B.
P+&0(+& "0-.0+,* /"#-,49 >
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
36/170?a
G-(0- K!:S..01(*(g,/(0+8+&(0+#$($(+"(1(/0-$]*#+,*()0.()#5/",*()0.()#M0-.0+,* /"#-,49
RO[M ),(*9 L
>7 R#& F0.4-#$$(0+ U#6(3#DSGF 0- H:FIJ 0+*9
7 :+30'-,) /0 / '4 ,+) ;,*Z ,-0'+)4#-(0)(3,**95 2*#X 3,*2 .'$3*#$ ,+) $(/ (+,+ ,($*# $#,/ ;"#+ 40$$(1*#
F= YXZXUXYH +89O !7GK78B8@K78;: ;B %=E8@KF 4K78=:79 K:E
4G;V
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
37/170?d
YXZXY !DGC8@KF VK78=:79
b0- $'-&(3,* 4,/(#+/$5 /"# 4-(.,-9 4-04"9*,3/(3 .#,$'-#$ )#4#+) 0+ /"# -($Z
$/-,/(2(3,/(0+ 02 /"# (+)(6()',* 4,/(#+/ ,+) /"# 3*(+(3,* $(/',/(0+ D!,1*# < "-*9
H:IF5 SGF5 KbG
8
8
L
F
.8C< +89O
I'--9 (+ 4,/(#+/
fd= 9#,-$
^=]d= 9#,-$ ;(/" ,+#X/-, -($Zo
;(/" .'*/(4*# -($Z 2,3/0-$oO,_0- $'--9 20- 3,+3#-
O,_0- /-,'.,5 I4(+,* F0-)S+_'-9
RO[M
b0+),4,-(+'X
RU]TbM5 Y "-*9
[,-2,-(+ SCV
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
38/170?@
o V($Z 2,3/0-$A
! 83/(6# 3,+3#-
! P1#$(/9 DLOS f?= Z&B.
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
39/170?Y
YX[ +*!N #!!$!!%$&" )(+ 52$$1*&/L0/" /"# GGI ,+) [#**$e I30-# )0 +0/ ,))-#$$ /"# -($Z 02 1*##)(+& #6#+/$7 !0,))-#$$ /"($ ($$'#5 $0.# 20-.$ 02 3*(+(3,* _')&.#+/$ ,-# -#E'(-#) ;"#+ ;#(&"(+&'4 /"# -($Z 02 /"-0.10$($ 6#-$'$ 1*##)(+& #6#+/$ ;(/" /"-0.104-04"9*,X($7 b0-/"($ 4'-40$#5 /"# SOGVPK: L*##)(+& V($Z I30-# ($ '$#) D!,1*# 7aX C0-.,* F= YX[H "
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
40/170?c
YX\ "*%*&/ #&1 *&*"*#"*(& () 4+(4.P2#T*!S$$'#$ -#*,/#) /0 /"# 04/(.,* /(.(+& 02 (+(/(,/(0+ ,+) )'-,/(0+ 02 4#-(]04#-,/(6#/"-0.104-04"9*,X($ (+ /"# 4#-(]04#-,/(6# $#//(+& ,+) (+ .#)(3,* 4,/(#+/$ -#.,(+'+$#//*#)7 !"# /(.(+& 02 (+(/(,/(0+ )#4#+)$ 0+ /"# 3*(+(3,* $(/',/(0+5 $4#3(2(34-04"9*,3/(3 ,+/ 02 3"0(3# ,+) /94# 02 ,+,#$/"#$(, '$#)7@Y5@c5Y=
"K>F= YX\H "8L8:C ;B ";VG;V= .& PU d]>= "- 40$/]04
b0+),4,-(+'X
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
41/170^=
YX^ #&"*_".+(%5("*3 ".$+#4P #&1 +$/*( #$!".$!*#!"# )#3($(0+ /0 4#-20-. $4(+,* 0- #4()'-,* ,+#$/"#$(,B,+,*$(, ,+) /"# /(.(+& 02
3,/"#/#- -#.06,* (+ , 4,/(#+/ -#3#(6(+& ,+/(/"-0.10/(3 /"#-,49 ($ .,)# 0+ ,+
(+)(6()',* 1,$($5 ;#(&"(+& /"# $.,**5 ,*/"0'&" )#2(+(/# -($Z 02 $4(+,* "#.,/0., ;(/"
/"# 1#+#2(/$ 02 -#&(0+,* ,+,#$/"#$(, 20- , $4#3(2(3 4,/(#+/7
P6#-,**5 /"# -($Z 02 3*(+(3,**9 $(&+(2(3,+/ 1*##)(+& (+3-#,$#$ ;(/" , ,$$03(,/#)
,1+0-.,*(/(#$ 02 /"# $4(+,* 30-) 0- 6#-/#1-,* 30*'.+5 /"# 4-#$#+3# 02 ,+ '+)#-*9(+&
30,&'*04,/"95 )(22(3'*/9 )'-(+& +##)*# 4*,3#.#+/5 ,+) ,+ (+);#**(+& +#'-,X(,*
3,/"#/#- )'-(+& $'$/,(+#) ,+/(30,&'*,/(0+5 4#-",4$ (+ , .'*/(2,3/0-(,* .,++#-7Y>S/$
1##+ 30+$($/#+/*9 -#40-/#) /",/ 4-0.4/ )(,&+0$($ ,+) (+/#-6#+/(0+ ($ +#3#$$,-9 /0
04/(.(g# +#'-0*0&(3 0'/30.#7
YX^XU 4K78=:79 G=@=8A8:C D:BGK@78;:K7=E = /0 >< "0'-$ ,2/#- , /"-0.104-04"9*,X($
)0$# ,+)
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
42/170^>
"K>F= YX^H /D8E=F8:=9 B;G $V8EDGKF 09= -87< #:78@;KCDFK:7 "< "0'-$ ,2/#-4-04"9*,3/(3 RO[M )0$# 0- "0'- ,2/#-+##)*# 4*,3#.#+/ D/"($ ($ (+ +#'-0,X(,* 1*03Z$;(/" (+/-,04#-,/(6# ,+/(30,&'*,/(0+J
F,/"#/#- -#.06,* < ] ^ "0'-$ ,2/#- *,$/ "#4,-(+)0$#
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
43/170^=
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
47/170^d
S2 /"# $30-# $'&$/$ /",/ UK! ($ '+*(Z#*95 +0 2'-/"#- (+6#$/(&,/(0+ ($ -#E'(-#)7 !"#'/(*(/9 02 U])(.#- (+ 3*(+(3,* 4-,3/(3# ",$ (/$ *(.(/,/(0+$7 !"#-# ,-# .,+9 30..#-3(,*U])(.#- ,$$,9$ 1'/ /"#9 *,3Z $/,+),-)($,/(0+ ,+) /"# ,44-04-(,/# 3'/]0226,*'#$7??? !"# ;"0*# 1*00) ,&&*'/(+,/(0+ .#/"0) 20- U])(.#- /#$/(+& /",/ ($ '$#)(+ .0$/ *,10-,/0-(#$ (+ O,*,9$(, ($ +0/ $#+$(/(6# (+ -'*(+& 0'/ K!:7>=d5>=Y5??? P+ /"#0/"#- ",+)5 /"#-# ,-# .,+9 3,'$#$ 20- , -,($#) U])(.#- D#7&7 (+2*,..,/(0+5
(+2#3/(0+5 +0-.,* 4-#&+,+395 3,+3#-5 ",#.,/0.,5 )($$#.(+,/#) (+/-,6,$3'*,-30,&'*,/(0+5 $'--9B /-,'.,5 $/-0Z#5 .903,-)(,* (+2,-3/(0+5 *(6#- 2,(*'-#5 -#+,*2,(*'-#5 4-#]#3*,.4$(, ,+) #3*,.4$(,5 #/37J ;"(3" *(.(/$ (/$ 6,*'# (+ /"# #X3*'$(0+02 K!: (+ /"# "0$4(/,*($#) 4,/(#+/$7???
#2/(+*".% )(+ 1," 1*#/&(!*!
3;DFE 87 >= 1,"k
#VVFM 1," -=FF9j 9@;G=
1," F8O=FM 1," D:F8O=FM
30!
4;9878A= &=CK78A=
4;9878A= &=CK78A= $W@FDE= 1,"
+=V=K7 30!8: U R==O
18KC:;9= 1,"K:E "G=K7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
48/170^@
ZXYXY 4DFL;:KGM $L>;F89L[#**$e F-(/#-(, ,$ )#$3-(1#) (+ !,1*# ?7>7< ;,$ ;#** /#$/#) (+ /"# 3*(+(3,* /#$/(+& /0.,+, +0+]4-#&+,+/ 4,/(#+/$ ;(/" $'$4#3/#) G:7
S2 /"# $30-# $'&$/$ *(Z#*9 G:5 306#- 4,/(#+/ ;(/" RO[M ,+) 4#-20-.30.4'/#-(g#) /0.0&-,4"9 4'*.0+,-9 ,+&(0&-,. DF!G8J 0+ /"# $,.# ),9 0-
;(/"(+ +#X/
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
49/170^Y
3.3 INVESTIGATIONS FOR CANCER8** 4,/(#+/$ )(,&+0$#) ;(/" '+4-060Z#) K!: ;"0 ,-# +0/ Z+0;+ /0 ",6# 3,+3#-$"0'*) 1# 022#-#) , 4"9$(3,* #X,.(+,/(0+ D2'-/"#- $4#3(2(3 /#$/$ &'()#) 19 /"#4,/(#+/e$ "($/0-9 ,+) #X,.(+,/(0+J5 , 3"#$/ k]-,9 ,+) 1*00) /#$/$ DbLF5 VG5 Rb!5'-(+,*9$($J7>>=
F0+$()#- 2'-/"#- (+6#$/(&,/(0+$ 20- 3,+3#- ;(/" ,+ ,1)0.(+0]4#*6(3 F! $3,+ D,+) ,.,..0&-,. 20- ;0.#+J (+ ,** 4,/(#+/$ ,) 06#- ^= 9#,-$ ;(/" , 2(-$/ '+4-060Z#)K!:7 !'.0'- .,-Z#-$ ,-# +0/ -#30..#+)#) 20- 3,+3#- $3-##+(+&7>>=
3.4 THROMBOPHILIA TESTING!"-0.104"(*(, .#,+$ , 4-#)($40$(/(0+ /0 3*0/ 20-.,/(0+7 S/ 3,+ #(/"#- 1# (+"#-(/#)0- ,3E'(-#)7 !"# Z+0;+ "#-(/,1*# /"-0.104"(*(,$ ,-# 2,3/0- K R#()#+5 4-0/"-0.1(++# .'/,/(0+ ,+) )#2(3(#+3(#$ 02 /"# +,/'-,* ,+/(30,&'*,+/$ D4-0/#(+ F5 4-0/#(+ I,+) ,+/(/"-0.1(+J7>>>5>>< !"#-# .,9 1# 0/"#- +#/(3 )#2#3/$ /",/ -#.,(+ /0 1#()#+/(2(#)7
b,3/0- K R#()#+ ,+) 4-0/"-0.1(+ +# .'/,/(0+ ,-# )($0-)#-$ 02 F,'3,$(,+$ ,+)-#3#+/ $/')(#$ ",6# $"0;+ /",/ /"#9 ,-# -,-# (+ :,$/ 8$(,7>>?5>>^ U#2(3(#+3(#$ 024-0/#(+ F5 4-0/#(+ I ,+) ,+/(/"-0.1(+ ,-# 6#-9 '+30..0+ 1'/ $##. /0 1# "(&"#-(+ :,$/ 8$(, ;"#+ 30.4,-#) /0 :'-04#7>>?5>>^
!"# .0$/ 30..0+ /"-0.104"(*(, ($ /"# ,3E'(-#) ,+/(4"0$4"0*(4() $9+)-0.#7 S/ ($,$$03(,/#) ;(/" 10/" ,-/#-(,* ,+) 6#+0'$ /"-0.10$($ ,$ ;#** ,$ -#3'--#+/4-#&+,+39 *0$$#$7>>a5>>d P/"#- -,-# ,3E'(-#) 3,'$#$ ,-# /"# .9#*04-0*(2#-,/(6#+#04*,$(, ,+) 4,-0X9$.,* +03/'-+,* ",#.0&*01(+'-(,7
!"-0.104"(*(, /#$/(+& )0#$ +0/ (+2*'#+3# /"# (+(/(,* .,+,.#+/ 02 , K!: +0- /"#(+/#+$(/9 02 ,+/(30,&'*,+/ /"#-,497>>>5>>>@]>>c V#3'--#+3# 02 K!: ,2/#- $/044(+&,+/(30,&'*,+/ /-#,/.#+/ ",$ +0/ 1##+ $"0;+ /0 1# 4-#)(3/,1*# 19 /"-0.104"(*(,/#$/(+& #X3#4/ (+ /"# 4-#$#+3# 02 /"# *'4'$ ,+/(30,&'*,+/ DR8JB ,+/(4"0$4"0*(4(),+/(10)(#$ D8G8J7>>>]>>?5>>a5>>c]>>>5>>
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
50/170^c
+=@;LL=:EK78;:9 /GKE=
U0 +0/ 022#- /"-0.104"(*(, /#$/(+& )'-(+& /"# ,3'/# /"-0.10/(3
#6#+/ 0- 4-(0- /0 (+(/(,/(0+ 02 ,+/(30,&'*,+/ /"#-,49
U0 +0/ 022#- /"-0.104"(*(, /#$/(+& /0 4,/(#+/$ ;"0 ,-# 30+/(+'(+&,+/(30,&'*,+/ /-#,/.#+/
F0+$()#- /#$/(+& 20- 8G8 ,+) R8 (+ 4,/(#+/$ ;"0 ",6# ",)'+4-060Z#) UK! 0- G: (2 (/ ($ 4*,++#) /0 $/04 ,+/(30,&'*,+//-#,/.#+/
F0+$()#- /#$/(+& 20- "#-#)(/,-9 /"-0.104"(*(, (+ 4,/(#+/$ ;"0",6# '+4-060Z#) UK! 0- G: ,+) ;"0 ",6# , 2(-$/])#&-## -#*,/(6#;"0 ",$ ",) , UK! 0- G: (2 (/ ($ 4*,++#) /0 $/04 ,+/(30,&'*,+//-#,/.#+/
U0 +0/ 022#- /"-0.104"(*(, /#$/(+& /0 4,/(#+/$ ;"0 ",6# ",) ,4-060Z#) UK! 0- G:
U0 +0/ 022#- /"-0.104"(*(, /#$/(+& (+ ;0.#+ ;(/" , 4-#6(0'$ K!:,$$03(,/#) ;(/" 4-#&+,+39 0- /"# 0-,* 30+/-,3#4/(6# 4(**
U0 +0/ 022#- /"-0.104"(*(, /#$/(+& /0 2(-$/])#&-## -#*,/(6#$ 024,/(#+/$ ;(/" /"-0.104"(*(, ;"0 ",6# ",) , UK! 0- G:
U0 +0/ 022#- /"-0.104"(*(, /#$/(+& /0 4,/(#+/$ ;"0 ",6# ",) ,+,-/#-(,* /"-0.10$($ 1'/ 30+$()#- 8G8 ,+) R8 (2 /"#-# ,-# +0 0/"#--($Z 2,3/0-$
U0 +0/ 022#- /"-0.104"(*(, /#$/(+& (+ -#3'--#+/ .($3,--(,$ 0-4-#&+,+39 *0$$#$ #X3#4/ 20- 8G8 ,+) R8
C#0+,/#$ ,+) 3"(*)-#+ ;(/" 4'-4'-, 2'*.(+,+$ $"0'*) 1# /#$/#)'-+/*9 20- 4-0/#(+ F 0- 4-0/#(+ I )#2(3(#+39
L
L
L
F
8
F
L
L
L
8
"K>F= ZX[H ";V
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
51/170a=
R0; .0*#3'*,- ;#(&"/ "#4,-(+ ($ 30+/(+'#) 20- ,/ *#,$/ a ),9$ 0- '+/(* /"# SCV ($,106# < 20- ,/ *#,$/ F= [XYXUH 2%-.9 K:E 7??]>?a5>?Y S/ )0#$ +0/ -#E'(-# .0+(/0-(+& ,+) (/e$ #,$# 02'$# .,Z#$ 0'/4,/(#+/ /-#,/.#+/ 2#,$(1*#7
F'--#+/*9 ,6,(*,1*# RO[M$ (+ O,*,9$(, ,+) -#30..#+)#) )0$#$ 20- /"#/-#,/.#+/ 02 ,3'/# K!: ,-# ,$ $"0;+ (+ !,1*# ^77>?^5>?c
> .&BZ& /;(3# ),(*9
!(+g,4,-(+D=7a ,+) =7@ .R 02 =J q >==#7&7 d= Z& 4,/(#+/ p =7a .Rj @= Z&
p =7d .Rj ^a Z& p =7?a .R /(+g,4,-(+J
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
52/170a>
[XYXY );:EKVKG8:DWb0+),4,-(+'X ($ ,+ (+)(-#3/ (+"(1(/0- 02 ,3/(6,/#) 2,3/0- k7 S/ )0#$ +0/ (+"(1(//"-0.1(+ ,+) ",$ +0 #22#3/ 0+ 4*,/#*#/$7 S/ ($ &(6#+ $'13'/,+#0'$*9 ,+) /"# )0$(+&20- /"# /-#,/.#+/ 02 K!: ($ 1,$#) 0+ /"# 10)9 ;#(&"/ D!,1*# ^7a .& /;(3# ,),9 ,$ /"# *0,)(+& )0$# 20- ? ;##Z$ 20**0;#) 19 ?=5>?d
[XYXZXU !R87@=
[XYXZXY !R87@K: 7; F= [XYXYH "
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
53/170a8CK7GK:8/ /"# /(.# 02 ;-(/(+& /"($ 34&5 ),1(&,/-,+ ($ +0/ *(3#+$#) 20- '$# (+ /"# /-#,/.#+/ 02K!:7
[XYX\ *:7GKA=:;D9 D:BGK@78;:K7=E ?d5>?Y
[XZ %#*&"$&3$ "+$#"%$&" () ,"$b0**0;(+& (+(/(,* "#4,-(+($,/(0+ 0- 20+),4,-(+'X (+ 4,/(#+/$ ;(/" K!:5 .,(+/#+,+3#02 ,+/(30,&'*,/(0+ ;(/" 0-,* ,+/(30,&'*,+/$ ($ -#30..#+)#)7 b0**0;(+& )($3",-/"0$# 0+ ;,-2,-(+ $"0'*) 1# 20**0;#) '4 ;(/"(+ , ;##Z ;(/" , -#4#,/ SCV7
S2 /"# SCV -#.,(+$ ;(/"(+ /"#-,4#'/(3 -,+ /"# $,.# )0$# ($ .,(+/,(+#) ,+) /"#+#X/ 20**0;]'4 ;(** 1# < ;##Z$ *,/#-7 S2 /"# SCV $/(** -#.,(+$ ;(/"(+ /"#-,4#'/(3
-,+ /"#+ .0+/"*9 20**0;]'4 ;(/" SCV ($ ,)6($#)7 O0-# 2-#E'#+/ 6($(/$ ,-#-#E'(-#) (2 /"#-,4#'/(3 SCV ($ +0/ ,3"(#6#) D$## 3",4/#- >=7=A O!8F][J7
Table 4.2.5: Management with IV UFH
h>7J ;"#/"#- /"# ,3'/# #4($0)# 02 K!: ",$ 1##+ #22#3/(6#*9 /-#,/#) ,+)
D7>J7>^=]>^?5>^d
!"# .0$/ (.40-/,+/ 2,3/0-$ /",/ (+2*'#+3# /"# -($Z 02 -#3'--#+3# ,2/#- $/044(+&,+/(30,&'*,+/ /"#-,49 ,-# /"# 4-#$#+3# 02 , -#6#-$(1*# 4-060Z(+& -($Z 2,3/0-5'+4-060Z#) D()(04,/"(3J K!: ,+) /"# 4-#$#+3# 02 ,3/(6# 3,+3#-7>^=5>^^?5>^@
8.0+& 4,/(#+/$ ;(/" K!: 4-060Z#) 19 , -#6#-$(1*# -($Z 2,3/0-5 /"# -($Z 02 -#3'--#+3#($ .'3" *0;#- (2 /"# 4-060Z(+& 2,3/0- ;,$ -#3#+/ $'--9 30.4,-#) ;(/" ,+0+$'-&(3,* /-(&- D#7&7 #$/-0+ /"#-,495 4-#&+,+395 *0+&]",'* 2*(&"/J7>^=5>^>5>^?
[XZXUXY +89O BK@7;G9 B;G 8:@G=K9=E >F==E8:C
!"# -($Z 2,3/0-$ 20- (+3-#,$#) 1*##)(+& (+ 4,/(#+/$ 0+ ,+/(30,&'*,/(0+ ,-# *($/#)1#*0; D!,1*# ^7?7>7^?5>^@
! T+4-060Z#) D()(04,/"(3J K!:
! G-#6(0'$ K!:
! O,*# +)#-
!83/(6# 3,+3#-
!8+/(4"0$4"0*(4() $9+)-0.#
! G-0X(.,* 6#-$'$ )($/,* UK!
! G0$/]/"-0.10/(3 $9+)-0.#
"K>F= [XZXUXUH +89O BK@7;G9 B;G G=@DGG=:@=
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
55/170
[XZXUXZ 3;LVF=78;: ;B K:78@;KCDFK78;:
!"#-# ($ +0 $/-0+& #6()#+3# /0 -#30..#+) -0'/(+# U])(.#- /#$/(+& 0- TI#X,.(+,/(0+ '40+ 30.4*#/(0+ 02 ,+/(30,&'*,/(0+ (+ 0-)#- /0 )#/#-.(+# K!:-#3'--#+3# ,+) /"# )#3($(0+ /0 4-0*0+& /"#-,495 '+*#$$ &'()#) 19 3*(+(3,*
$9.4/0.$7?>>5?>^>
a^
!"# -#30..#+)#) )'-,/(0+ 02 ,+/(30,&'*,/(0+ "#+3# )#4#+)$ 0+ /"# -($Z 02-#3'--#+3# ,+) /"# -($Z 02 1*##)(+& D!,1*# ^7?7>J7>^^?5>^a
G-060Z#) 19 , /-,+$(#+/ $'-&(3,* ? .0+/"$
-($Z 2,3/0-
G-060Z#) 19 , /-,+$(#+/ +0+$'-&(3,* ? .0+/"$
-($Z 2,3/0-
T+4-060Z#) K!: ,+) 0+# 0- .0-# ? .0+/"$
1*##)(+& -($Z
T+4-060Z#) K!: (+ ,$$03(,/(0+;(/" ,3/(6# 3,+3#- ,+) /"#,+/(]4"0$4"0*(4() $9+)-0.#
8+/(30,&'*,/(0+ ($ 30+/(+'#) ,$*0+& ,$ /"# -($Z 2,3/0- -#.,(+$
T+4-060Z#) K!: P22#- (+)#2(+(/# ,+/(30,&'*,/(0+ ,2/#-
/,Z(+& (+/0 ,330'+/A
G,/(#+/e$ 4-#2#-#+3#
R0; 1*##)(+& -($Z
H00) ,+/(30,&'*,+/ .0+(/0-(+&
($ ,3"(#6,1*#
)8G97 ,"$ +=@;LL=:E=E 1DGK78;: ;B #3
! T+30+/-0**#) "94#-/#+$(0+
!8 f@a 9#,-$
! V#+,* (.4,(-.#+/
!8+,#.(,
! V#3#+/ .,_0- 1*##)(+&
"K>F= [XZXUXYH +89O BK@7;G9 B;G 8:@G=K9=E >F==E8:C
"K>F= [XZXUH 1DGK78;: ;B K:78@;KCDFK78;: `/GKE= 5 +=@;LL=:EK78;:a
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
56/170aa
[X[ ".+(%5(2P"*3 ".$+#4P
[X[XU 4DFL;:KGM =L>;F89L
["#-# *(2#]/"-#,/#+(+& .,$$(6# G: 033'-$5 3,-)(0-#$4(-,/0-9 -#$'$3(/,/(0+ ($'$',**9 -#E'(-#) ,+) (+/-,6#+0'$ "#4,-(+ &(6#+7 !"-0.10*9/(3 /"#-,495
4#-3'/,+#0'$ 3,/"#/#- /"-0.1'$ 2-,&.#+/,/(0+ 0- $'-&(3,* #.10*#3/0.9 ;(**1# -#E'(-#)7 !"($ ;(** 6,-9 ;(/" *03,* #X4#-/($#7>a?
[X[XUXU 4DFL;:KGM =L>;F=@7;LM
!"($ 4-03#)'-# ($ 6#-9 -,-#*9 )0+# ,+) ",$ , "(&" 4#-(]04#-,/(6# .0-1()(/9 ,+).0-/,*(/9 -,/#$ D?=]a=nJ7>a@ M0;#6#-5 /"# *0+&]/#-. 0'/30.# 20- $'-6(60-$ ($&00)7 S/ ($ (+)(3,/#) (+ .,$$(6# G: D4-06#+ 19 (.,&(+& .0),*(/(#$J ;(/"",#.0)9+,.(3 30.4-0.($#7 S/ ($ )0+# ,$ ,+ #.#-+39 4-03#)'-# 20**0;(+&2,(*#) 30+$#-6,/(6# .#,$'-#$ (+3*')(+& /"-0.10*9$($7>ad
V#3#+/*95 4#-3'/,+#0'$ 3,/"#/"#-])(-#3/#) #.10*#3/0.9 )#6(3#$ ",) 1##+)#6#*04#)7 !"#$# ,-# E'(3Z#- ,+) #,$(#- /0 4#-20-.7 !"($ 3,+ 1# ,'&.#+/#)19 /"# ,).(+($/-,/(0+ 02 /"-0.10*9/(3 )-'&$5 ;"(3" $4##)$ '4 3*0/2-,&.#+/,/(0+7>^Y5>a=5>a>
[X[XY 1==V ,=8: ";989
["#-# UK! /"-#,/#+$ *#& 6(,1(*(/9 /"-0'&" 6#+0'$ &,+&-#+#5 /"# *#& $"0'*) 1##*#6,/#)5 ,+/(30,&'*,/(0+ 30..#+3#) ,+) 30+$()#-,/(0+ &(6#+ /0 6#+0'$
/"-0.1#3/0.9 0- /"-0.10*9/(3 /"#-,497 F,/"#/#-])(-#3/#) /"-0.10*9$($ ($4-#2#--#) /0 $9$/#.(3 /"-0.10*9$($7>aaY
8+/(30,&'*,/(0+ $"0'*) 1# -#$'.#) ,2/#- (+$#-/(0+ 02 3,6,* 2(*/#-$ '+*#$$ (/ ($30+/-,(+)(3,/#)7>ac!"# *0+&]/#-. #22#3/$ 02 SKF 2(*/#-$ ,-# '+/#$/#)5 /"#-#20-#2(*/#-$ $"0'*) 1# $,2#*9 -#.06#) 0+3# /"#-# ($ +0 -($Z 02 #.10*(7 O0$/ 2(*/#-$ 3,+
1# -#.06#) 1#/;##+ >^ /0 7 F0+/-,(+)(3,/(0+ /0 ,+/(30,&'*,/(0+
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
58/170a@
G,/(#+/$ ;"0 ",) SKF 2(*/#- (+$#-/(0+ OTI! 1# &(6#+ , ),/# 20- -#.06,* 02 /"#2(*/#- ;(/" /"# $/(4'*,/#) /(.# ,330-)(+& /0 /"# .,+'2,3/'-#-e$ -#30..#+),/(0+7M#+3# (/ ($ /"# )'/9 02 /"# 4-,3/(/(0+#- /0 #$/,1*($" , -#3,** $9$/#. /0 #+$'-#4,/(#+/ ($ +0/ *0$/ /0 20**0;]'47>aY
[X^ 4+$,$&"*(& () 4(!"_".+(%5("*3 !P&1+(%$!"# .0$/ 30..0+ 30.4*(3,/(0+ 02 K!: ($ 3"-0+(3 6#+0'$ (+$'22(3(#+39 DFKSJ*#,)(+& /0 40$/]/"-0.10/(3 $9+)-0.# DG!IJ7 G0$/]/"-0.10/(3 $9+)-0.# -#$'*/$(+ )#1(*(/,/(+& 4,(+5 $;#**(+&5 ,+) '*3#-,/(0+ ,+) ($ , $(&+(2(3,+/ 3,'$# 02 *0$$ 02;0-Z(+& ),9$7 S/ 3,+ 30+/-(1'/# /0 ,+ (+3-#,$# (+ -#3'--#+/ UK! ,+) G:7>d>
G-#6#+/(0+ 02 G!I ;(** $(&+(2(3,+/*9 -#)'3# /"# .0-1()(/9 ,+) *,/# .0-/,*(/9 02UK!7>dda5>@> R,10-,/0-(#$$"0'*) )#/#-.(+# /"# 8G!! -,+ /",/ 30--#$40+)$ /0 /"# .#,$'-#) *#6#*$ 02"#4,-(+ ,3/(6(/9 &(6#+7
\XY -#+)#+*&G-(0- /0 (+(/(,/(0+ 02 ;,-2,-(+ /"#-,495 $,.4*#$ $"0'*) 1# )-,;+ 20- G! ,+) 8G!!
/0 #$/,1*($" , 1,$#*(+#7 8 2(-$/ $,.4*# 20- SCV ($ /,Z#+ < /0 ? ),9$ ,2/#- /"# (+(/(,/(0+02 ;,-2,-(+ ,+) .0+(/0-#) #6#-9 < /0 ^ ),9$ '+/(* /"# SCV ($ (+ /"# 4,/(#+/e$ /,-/-,+ ,2/#- ;"(3" (/ 3,+ 1# .0+(/0-#) ;##Z*97>@=5>@>
P+3# /"#-,4#'/(3 *#6#* ($ ,3"(#6#) ,+) ($ 30+$($/#+/ 20- < 30+$#3'/(6# -#,)(+&$5SCV /#$/(+& ($ /"#+ 3,--(#) 0'/ #6#-9 < ;##Z$5 /"#+ ^ ;##Z*9 (2 /"# SCV -#.,(+$$/,1*#7 b0- 4,/(#+/$ 0+ *0+&]/#-. ,+/(30,&'*,/(0+ ;(/" 30+$($/#+/*9 $/,1*# SCV$5/#$/(+& 3,+ 1# )0+# #6#-9 >< ;##Z$7>@=5>@a
b0- .0$/ (+)(3,/(0+$5 , /"#-,4#'/(3 -,+ 02 @=5>@>
\XZ 0&)+#3"*("$1 .$4#+*&!"# 8G!! ",$ 1##+ ;()#*9 '$#) 20- .0+(/0-(+& /"#-,4#'/(3 )0$#$ 02 TbM7 8/,-/ -,/(0 02 >7a /0 da5>dd5>dc
I/,+),-)(g,/(0+ 1#/;##+ *,10-,/0-(#$ (+ /"# 30+/-0* 02 "#4,-(+ /"#-,49 '$(+& /"#8G!! ",$ +0/ 1##+ ,3"(#6#) 1#3,'$# 02 /"# 30+$()#-,1*# -#,+/ ,+) (+$/-'.#+/6,-(,1(*(/9 #.4*09#) (+ /"# 8G!!5 ;"(3" -#$'*/$ (+ (+30+$($/#+39 (+ $#+$(/(6(/9 /0"#4,-(+7>d@5>dY5>@< R,10-,/0-(#$ ,-# +0; .06(+& /0;,-)$ ,+/(]k, 20- .0+(/0-(+&/-#,/.#+/ ;(/" TbM7>dd5>dY5>@@^5>@@
M#4,-(+ -#$($/,+3# ($ 30..0+ (+ 4-#&+,+39 .,Z(+& 8G!! .0+(/0-(+& '+-#*(,1*#;(/" /"# ),+- 02 06#-]"#4,-(+($,/(0+ ;(/" '+2-,3/(0+,/#) "#4,-(+7 b'-/"#-.0-#/"# 8G!! -,/(0 '$#$ 30+/-0* 4*,$., 2-0. +0-.,* (+)(6()',*$ ,+) +0/ 2-0. 4*,$.,02 4-#&+,+/ ;0.#+7>dd5>d@
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
60/170ac
\X[ 2(- %(2$302#+ -$*/." .$4#+*&R0; .0*#3'*,- ;#(&"/ "#4,-(+ DRO[MJ ",$ , "(&"*9 4-#)(3/,1*# ,+/(30,&'*,+/-#$40+$# 1#3,'$# 02 (/$ #X3#**#+/ 1(0,6,(*,1(*(/9 ,+) "#+3# )0#$ +0/ -#E'(-#.0+(/0-(+&7 M0;#6#- (+ $0.# 3*(+(3,* $#//(+&$ $'3" ,$ -#+,* (.4,(-.#+/ D)#*,9#)3*#,-,+3# 02 RO[MJ5 4-#&+,+39 ;(/" .#3",+(3,* "#,-/ 6,*6#$ ,+) +#0+,/#$5.0+(/0-(+& "#4,-(+ ;(/" ,+/(]k, ,3/(6(/9 ,$$,9 19 /"# 3"-0.0+(3 .#/"0) .,9
1# '$#2'* (2 /"#-# ($ , 30+3#-+ 02 06#-] 0- '+)#-]30,&'*,/(0+7>da5>dc5>@=
M0;#6#-5 /"# ,+/(]k, ,$$,9 ",$ $(&+(2(3,+/ *(.(/,/(0+$7 U(22#-#+/ RO[M4-#4,-,/(0+$ ",6# )(22#-#+/ ,+/(]SS, ,3/(6(/9 (+ -#*,/(0+ /0 ,+/(]k, ,3/(6(/97 !"#)#&-## 02 ,+/(30,&'*,/(0+ 02 )(22#-#+/ RO[M$ .,9 +0/ 1# 30.4,-,1*# ,/ /"#$,.# 4*,$., ,+/(]k, 30+3#+/-,/(0+7>@?5>@d
O0+(/0-(+& 02 RO[M '$(+& ,+/(]k, ,$$,9 -#E'(-#$ 3,-#2'* ,$$,9 6,*(),/(0+54-06()#$ ,+ (+30.4*#/# 4(3/'-# 02 /"# ,+/(30,&'*,+/ #22#3/ ,+) ($ 400-*94-#)(3/(6# 02 ,+/(/"-0.10/(3 #22(3,39 ,+) -($Z 02 ",#.0--",>@?5>@d
S2 RO[M ($ .0+(/0-#)5 /"# 1*00) $,.4*# $"0'*) 1# )-,;+ ,44-0X(.,/#*9 ^"0'-$ ,2/#- $'13'/,+#0'$ (+_#3/(0+7 S2 ,33'.'*,/(0+ 02 RO[M ($ $'$4#3/#)520- #X,.4*# (+ -#+,* 2,(*'-#5 , /-0'&" *#6#* 0+ , $,.4*# /,Z#+ da5>dc5>@=
\X\ )(&1#4#+*&0Tb0+),4,-(+'X 4-0)'3#$ , 4-#)(3/,1*# ,+/(30,&'*,+/ -#$40+$# ,+) )0#$ +0/ -#E'(-#
.0+(/0-(+&7 S2 -#E'(-#)5 20+),4,-(+'X 3,+ 1# .#,$'-#) '$(+& 20+),4,-(+'X]$4#3(2(3,+/(]k, ,3/(6(/97?>?
\X^ +*,#+(T#5#&V(6,-0X,1,+ ",$ 4-#)(3/,1*# 4",-.,30Z(+#/(3$ ,+) )0#$ +0/ -#E'(-# .0+(/0-(+&7?>^
S2 -#E'(-#)5 -(6,-0X,1,+ 3,+ 1# .#,$'-#) '$(+& -(6,-0X,1,+]$4#3(2(3 ,+/(]k,,3/(6(/97?>^
+=@;LL=:EK78;:9 /GKE=
!"# S+/#-+,/(0+,* C0-.,*($#) V,/(0 DSCVJ ($ '$#) /0 .0+(/0-;,-2,-(+
8
b0- .0$/ (+)(3,/(0+$5 /"# /,-/ SCV ($
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
61/170d=
L
8
8
8
8
8
8
8
L
L
8
8
8
b0- 4,/(#+/$ 0+ *0+&]/#-. ,+/(30,&'*,/(0+ ;(/" 30+$($/#+/*9$/,1*# SCV$5 SCV /#$/(+& 3,+ 1# )0+# #6#-9 >< ;##Z$
!"#-# ($ +0 .,X(.'. ;,-2,-(+ )0$# /0 .,(+/,(+ , /"#-,4#'/(3-,+
O0+(/0-(+& 4-04"9*,3/(3 )0$#$ 02 TbM ($ +0/ -#E'(-#)
O0+(/0-(+& /"#-,4#'/(3 )0$#$ 02 TbM 3,+ 1# ,3"(#6#) '$(+&/"# 8G!!7 M0;#6#- *03,* 3,*(1-,/(0+ 02 /"# /#$/ '$(+& ,+/(]k, 0-4-0/,.(+# /(/-,/(0+ .'$/ 1# 3,--(#) 0'/ /0 )#/#-.(+# /"#-#30..#+)#) /,-/ 8G!! -,/(0 02 >7a]
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
62/170d>
\Xb .$4#+*&_*&103$1 ".+(%5(3P"(4$&*# #&1 %(&*"(+*&/
42#"$2$" 3(0&"!
\XbXU *:7G;ED@78;:
8** 4,/(#+/$ -#3#(6(+& ,+9 "#4,-(+ $"0'*) ",6# , 1,$#*(+# 4*,/#*#/ 30'+/ ,$
"#4,-(+](+)'3#) /"-0.1039/04#+(, ,+) /"-0.10$($ DMS!!J ($ , Z+0;+ 30.4*(3,/(0+
02 "#4,-(+$7 MS!! ($ 3,'$#) 19 /"# )#6#*04.#+/ 02 S&H ,+/(10)(#$ )(-#3/#) ,&,(+$/, 30.4*#X 02 4*,/#*#/ 2,3/0- ^ DGb^J ,+) "#4,-(+7 !"# S&HB Gb^B "#4,-(+ 30.4*#X#$
1(+) /0 ,+) ,3/(6,/# 4*,/#*#/$ /"-0'&" /"#(- b3 -#3#4/0-$ -#$'*/(+& (+ , 4-0/"-0.10/(3
30+)(/(0+ /",/ ($ ,$$03(,/#) ;(/" 6#+0'$ ,+) ,-/#-(,* /"-0.10$($7?>a5?>d
!"# (+3()#+3# 02 MS!! ($ &-#,/#- ;(/" 106(+# /",+ ;(/" 4-03(+# "#4,-(+ ,+) &-#,/#-
;(/" '+2-,3/(0+,/#) "#4,-(+ /",+ ;(/" RO[M Dan 6$7 =7anJ7 !"# 2-#E'#+39 02 MS!!
($ &-#,/#- (+ $'-&(3,* /",+ .#)(3,* 4,/(#+/$7?>a5?>d
\XbXY 4FK7=F=7 L;:87;G8:C
8** 40$/]04#-,/(6# 4,/(#+/$ 0+ '+2-,3/(0+,/#) "#4,-(+ $"0'*) ",6# /"#(- 4*,/#*#/
30'+/$ .0+(/0-#)5 ;"(*# /"0$# 0+ RO[M $"0'*) ",6# /"#(- 4*,/#*#/ 30'+/$
.0+(/0-#) 0+*9 ,2/#- 3,-)(04'*.0+,-9 194,$$ D!,1*# a7@7a5?>d
+@;LL=:EK78;:9 /GKE=
G,/(#+/$ ;"0 ,-# /0 -#3#(6# ,+9 "#4,-(+ $"0'*) ",6# , 1,$#*(+#4*,/#*#/ 30'+/
F
G0$/]04#-,/(6# 4,/(#+/$5 (+3*')(+& 01$/#/-(3 3,$#$5 -#3#(6(+& TbM$"0'*) ",6# 4*,/#*#/ 30'+/ .0+(/0-(+& 4#-20-.#) #6#-9 ^ '+/(* "#4,-(+ ($ $/044#)
F
G0$/]3,-)(04'*.0+,-9 194,$$ 4,/(#+/$ -#3#(6(+& RO[M $"0'*)
",6# 4*,/#*#/ 30'+/ .0+(/0-(+& 4#-20-.#) #6#-9 ^ '+/(* "#4,-(+ ($ $/044#)
F
G0$/]04#-,/(6# 4,/(#+/$ D0/"#- /",+ 3,-)(04'*.0+,-9 194,$$4,/(#+/$J -#3#(6(+& RO[M )0 +0/ +##) -0'/(+# 4*,/#*#/ .0+(/0-(+&
F
G0$/]04#-,/(6# 4,/(#+/$ ,+) 3,-)(04'*.0+,-9 194,$$ 4,/(#+/$;"0 ",6# 1##+ #X40$#) /0 "#4,-(+ (+ /"# 4-#6(0'$ >== ),9$ ,+),-# -#3#(6(+& ,+9 /94# 02 "#4,-(+ $"0'*) ",6# , 4*,/#*#/ 30'+/)#/#-.(+#) F= \XbXYH %;:87;G8:C VFK7=F=7 @;D:79 EDG8:C
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
63/170dY?
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
65/170d^
3F8:8@KF 8:E8@K78;: B;G RKGBKG8: 7G8FFK78;: 4G;97;F89L
V#3#+/ K!:Dh? .0+/"$J
FM8UI7 FM8UIF==E8:C G89O
"K>F= ^XYH +89O 97GK78B8@K78;: B;G V=G8;V=GK78A= 7;=L>;F89L
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
66/170da
I4(+,* $'--9AS+/-,3-,+(,* $'--95(+/-,]$4(+,* $'--9
F0*0+ 40*94#3/0.9D0+&0(+& 1*##)(+& 2-0.40*94 $/,*Z -#$#3/(0+$(/#J
:9#AF,/,-,3/ -#.06,*
O,_0- 0-/"04,#)(3$'--95 -#30+$/-'3/(6#4*,$/(3 $'--9
T-0+(/,* $'--9AG-0$/,/# ,+) 1*,))#--#$#3/(0+
O,_0- 3,+3#- $'--9
F,-)(,3 4,3#.,Z#-(.4*,+/,/(0+D'+0440$#) /($$'#*,9#-$ 02 /"# 4,3#.,Z#-403Z#/ "#,* 19$#30+),-9 (+/#+/J
^X[ %#/*&/ #&"*3(#/02#"*(& *& !0+/$+P
^X[XU -KGBKG8: 8:7=GGDV78;:[,-2,-(+ (+/#--'4/(0+ ($ +0/ -#E'(-#) 20- .(+0- $'-&(3,* 4-03#)'-#$ ;(/" *0; -($Z 02
1*##)(+&7 [,-2,-(+ (+/#--'4/(0+ ($ -#E'(-#) 20- "(&" 1*##)(+& -($Z $'--(#$7 ["#+;,-2,-(+ ($ $/044#)5 1-()&(+& /"#-,49 ;(/" RO[M5 20+),4,-(+'X 0- SK TbM ($
(+)(3,/#) 20- "(&" -($Z &-0'4 ,+) 3,$#]19]3,$# 20- .0)#-,/# -($Z &-0'4 20-
/"-0.10#.10*($.7>Y>]>Y?
S/ /,Z#$ ,44-0X(.,/#*9 a ),9$ ,2/#- $/044(+& ;,-2,-(+ 20- /"# SCV /0 +0-.,*(g#7>cca
8 $,2# SCV 20- .,_0- $'--(#$ ($ h>7a ,+) h>7< 20- +#'-0$'--(#$7 [,-2,-(+ 3,+
1# -#$'.#) >< /0 @Y]>Y?
V#$'.(+& /"#-,4#'/(3 RO[M 0- 20+),4,-(+'X ,2/#- $'--9 ;(** )#4#+) 0+
;"#/"#- ",#.0$/,$($ ($ $#3'-#)j (+ +#-,* 20- $'--(#$ ;(/" "(&" 1*##)(+& -($Z5
RO[M 0- 20+),4,-(+'X ($ -#$'.#) ,2/#- ^Y /0 @< "0'-$j 20- $'--(#$ ;(/" *0;
1*##)(+& -($Z5 RO[M 0- 20+),4,-(+'X ($ -#$'.#) ,2/#-
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
67/170dd
6.4.3 The novel oral anticoagulants
!;0 +06#* 0-,* ,+/(30,&'*,+/$ DCP8F$J5 ),1(&,/-,+ ,+) -(6,-0X,1,+ ",6#-#3#+/*9 1##+ ,44-06#)7 U,1(&,/-,+ ($ *(3#+$#) 20- '$# (+ $/-0Z# 4-#6#+/(0+ (++0+]6,*6'*,- ,/-(,* 2(1-(**,/(0+ ,+) (+ K!: 4-#6#+/(0+ (+ "(4 ,+) Z+## $'--97L#$()#$ $/-0Z# ,+) K!: 4-#6#+/(0+ ,$ 20- ),1(&,/-,+5 -(6,-0X,1,+ ($ ,*$0 *(3#+$#)20- '$# ,$ ,+ 04/(0+ 20- /"# /-#,/.#+/ 02 UK! ,+) G:7
3;:78:D=RKGBKG8:
-KGBKG8:8:7=GGDV78;:
5G8EC8:C &; >G8EC8:C
R0; 1*##)(+&
-($Z $'--(#$
M(&" 1*##)(+&
-($Z $'--(#$
M(&"B.0)#-,/#
/"-0.10]#.10*(3-($Z
R0;
/"-0.10]#.10*(3-($Z
"K>F= ^X[H %K:KC8:C RKGBKG8: K:78@;KCDFK78;: 8: 9DGC=GM
+=@;LL=:EK78;:9 /GKE=
:*#3/(6# $'--9 $"0'*) 1# ,60()#) (+ /"# 2(-$/ .0+/" ,2/#- ,+ ,3'/##4($0)# 02 K!:
[,-2,-(+ $"0'*) 1# $/044#) ,/ *#,$/ a ),9$ 1#20-# $'--9
[,-2,-(+ $"0'*) 1# -#$/,-/#) >< /0
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
68/170d@
8 +0-.,* /"-0.1(+ /(.# -'*#$ 0'/ /"# 4-#$#+3# 02 (.40-/,+/ *#6#*$ 02),1(&,/-,+j /"($ /#$/ 30'*) 1# '$#) 4-#]04#-,/(6#*9 (+ 4,/(#+/$ (+ ;"0. /"#-#($ , 40/#+/(,* 20- 4#-$($/#+/ ,+/(30,&'*,+/ #22#3/5 0- 20- /"0$# '+)#-&0(+&$'--9 ;(/" , "(&" -($Z 02 30.4*(3,/(0+$ 2-0. 1*##)(+&5 $'3" ,$ $4(+,* 0-+#'-0$'--97?>@5?>Y G-0/"-0.1(+ /(.# .,9 1# 4-0*0+) (+ -(6,-0X,1,+ 1'//"($ )0#$ +0/ -#*(,1*9 4-#)(3/ -(6,-0X,1,+ *#6#*$7?>@
M,*2]*(2#5 "0'-$F,*3'*,/#)3-#,/(+(+#
3*#,-,+3#5 .RB.(+
!(.(+& 02 *,$/ )0$# 1#20-# $'--9
R0; 1*##)(+& -($Z M(&" 1*##)(+& -($Z
>? D>> ]
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
69/170dY
6.4.3.2. Post-operative management!"# /(.# 40(+/ 20- /"# -#$'.4/(0+ 02 ),1(&,/-,+ 0- -(6,-0X,1,+ )#4#+)$ ,*.0$/
#X3'$(6#*9 0+ /"# 40$/]04#-,/(6# -($Z 02 1*##)(+&7 b0- 4-03#)'-#$ ;(/" &00)
",#.0$/,$($ $"0-/*9 ,2/#- /"# #+) 02 /"# 4-03#)'-#5 -#$'.4/(0+ 02 )-'& ($
-#30..#+)#) ,2/#- , .(+(.'. 02 ^ /0 d "0'-$ 20**0;(+& $'--97?>@
b0- ),1(&,/-,+5 , ",*2])0$# D@a .&J ($ -#30..#+)#) 20- /"# 2(-$/ )0$#5 ,+)/"#-#,2/#- /"# '$',* .,(+/#+,+3# )0$#7 b0- -(6,-0X,1,+5 , >= .& )0$# ($
-#30..#+)#) 20- /"# 2(-$/ )0$#7 G,/(#+/$ ;(/" 10;#* 4,-,*9$($ .,9 -#E'(-#
1-()&(+& ;(/" 4,-#+/#-,* ,+/(30,&'*,+/$ '+/(* /"#9 ,-# ,1*# /0 /0*#-,/# 0-,**97?>@
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
70/170dc
bXf %#/$%$&" () (,$+_#&"*3(#/02#"*(&
bXU -#+)#+*& #&1 52$$1*&/8+/(30,&'*,/(0+ ;(/" ;,-2,-(+ ($ 6#-9 #22#3/(6# (+ /"# 4-#6#+/(0+ ,+) /-#,/.#+/ 02
/"-0.10#.10*(3 #6#+/$7 M0;#6#-5 .,_0- 1*##)(+& 30.4*(3,/(0+$ *#,)(+& /0
"0$4(/,*($,/(0+ ,+) )#,/" ",$ 1##+ -#40-/#) (+ > /0 Yn 02 4,/(#+/$ )'-(+& #,3" 9#,-
02 *0+&]/#-. ;,-2,-(+ /"#-,497>cY5cc]
!"# 04/(.,* (+/-,6#+0'$ )0$# 02 6(/,.(+ 20- 4,-/(,* -#6#-$,* 02 06#-];,-2,-(+($,/(0+
($ =7a /0 >7= .&7 S2 2'** 30--#3/(0+ 02 /"# SCV ($ )#$(-#)5 *,-- )0$#$ ,-# +##)#)7 !"#
SCV 3,+ '$',**9 1# +0-.,*(g#) ;(/"(+
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
71/170@=
b0'-]2,3/0- GFF$ ,-# ,1*# /0 30.4*#/#*9 -#6#-$# ;,-2,-(+](+)'3#) ,+/(30,&'*,/(0+;(/"(+ >= .(+'/#$ 1'/ /"# (+2'$#) 3*0//(+& 2,3/0-$ ",6# , 2(+(/# ",*2]*(2#5 /"# $"0-/#$/02 ;"(3" ($ 2,3/0- KSS ,/ d "0'-$7 b0- /"($ -#,$0+5 a .& 02 (+/-,6#+0'$ 6(/,.(+ `$"0'*) 1# &(6#+ ;(/" /"# GFF7=.(+'/#$ (+ *(2#]/"-#,/#+(+& 1*##)(+&75F==E8:C VK78=:79!"# -($Z 02 1*##)(+& (+3-#,$#$ #X40+#+/(,**9 ;(/" (+3-#,$(+& SCV7 G,/(#+/$ ;(/" SCV.0-# /",+ Y ,-# ,/ , $(&+(2(3,+/*9 "(&" -($Z 02 1*##)(+&7 /0 a .& 0-,* 6(/,.(+ `7 8/ /"#$# )0$#$06#-]30--#3/(0+ ($ (+2-#E'#+/ ,+) -#$($/,+3# /0 -#],+/(30,&'*,/(0+ )0#$ +0/033'-7>cc55>5
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
72/170@>
3F8:8@KF !@=:KG8;9 +=@;LL=:EK78;:9 /GKE=
O,_0- L*##)(+&DR(2# B R(.1!"-#,/#+(+&J
L
L
L
F
C0+]O,_0-L*##)(+&
b0- ,** 30+$()#-A
!#.40-,-9 )($30+/(+',/(0+ 0- )0$# -#)'3/(0+02 ;,-2,-(+ D)#4#+)(+& 0+ 3*(+(3,* $3#+,-(0J
SK 6(/,.(+ `A > /0 ? .&
L
L
:*#6,/#) SCV
DC0 1*##)(+&J
>7SCV fa7=hY7=
D7 hc 8: :;:_>F==E8:C VK78=:79
!"# )#3($(0+ /0 &(6# 6(/,.(+ ` /0 , +0+]1*##)(+& 4,/(#+/ ;(/" SCV hY ($ .0-#
30+/-06#-$(,*7 S/ ($ -#,$0+,1*# /0 30+$()#- &(6(+& 0-,* 6(/,.(+ ` /0 4,/(#+/$ ;(/" ,+ SCV
1#/;##+ a7= /0 Y7= (2 /"#9 ,-# _')) /0 1# ,/ "(&" -($Z 02 1*##)(+&5 1'/ (/ ($ +0/
+#3#$$,-9 /0 022#- /"($ -0'/(+#*9 /0 ,** 4,/(#+/$7 [(/"0*)(+& > /0 < )0$#$ 02 ;,-2,-(+ ,+)
-#)'3(+& .,(+/#+,+3# )0$# .,9 1# ,** /",/ ($ -#E'(-#)7>cY5a STBZ&
" SCV fa7= &(6# ?= STBZ&
b0- (+/-,3-,+(,* ",#.0--", )0$#$ 02 '4 /0a= STBZ& 3,+ 1# &(6#+
S2 GFF +0/ ,6,(*,1*#5 &(6# bbG >a /0
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
73/170@8CK7GK:
S2 )#/#3/#) $00+ ,2/#- (+$/(0+ /"# ,1$0-4/(0+ 02 ),1(&,/-,+ .,9 1# -#)'3#) 19 /"#
,).(+($/-,/(0+ 02 ,3/(6,/#) 3",-30,*7 !"#-# ($ 3'--#+/*9 +0 ,+/()0/# 20- /"#
,+/(30,&'*,+/ #22#3/ 02 ),1(&,/-,+7 b-#$" 2-0g#+ 4*,$.,5 GFF 0- -bKSS, ",6# +0/
1##+ )#.0+$/-,/#) /0 -#6#-$# 1*##)(+& 30.4*(3,/(0+$ )'# /0 ),1(&,/-,+7?
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
77/170@d
cXf ,$&(0! ".+(%5($%5(2*!% *& (5!"$"+*3!
cXU *&"+(103"*(&K#+0'$ /"-0.10#.10*($. 30.4*(3,/#$ 1#/;##+ > (+ a== ,+) > (+
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
78/170@@
cXZXZ +KE8;F;C8@ =AKFDK78;:!"#-# ,-# +0 $9$/#.,/(3 )(22#-#+3#$ (+ /"# )(,&+0$/(3 $/-,/#&(#$ 20- )##4 6#+0'$/"-0.10$($ ,+) 4'*.0+,-9 #.10*($. (+ /"# 4-#&+,+/ ,+) /"# +0+]4-#&+,+/4,/(#+/7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
79/170@Y
cXZXZXYXY 3" VDFL;:KGM K:C8;CGKVB
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
80/170@c
cX[XY 4DFL;:KGM =L>;F89L
S2 /"# 3*(+(3,* $'$4(3(0+ 02 G: ($ "(&"5 , KB\ $3,+ 0- F!G8 $"0'*) 1# 4#-20-.#)7
["#-# 2#,$(1*#5 ;0.#+ $"0'*) 1# (+60*6#) (+ /"# )#3($(0+ /0 '+)#-&0 F!G8 0-
KB\ $3,++(+&7 S)#,**9 (+20-.#) 30+$#+/ $"0'*) 1# 01/,(+#) 1#20-# /"# /#$/$ ,-#
'+)#-/,Z#+7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
81/170Y=
O,$$(6# *(2#]/"-#,/#+(+& G: $"0'*) 1# /-#,/#) ;(/" (+(/(,* (+/-,6#+0'$ "#4,-(+ 20**0;#)19 (..#)(,/# /"-0.10*9$($ ;(/" /"-0.10*9/(3 /"#-,49 0- $'-&(3,* #.10*#3/0.9 D$##$#3/(0+ ^7^J7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
82/170Y>
cX\X^ +=C8;:KF K:K=97;DG K:E E=F8A=GMV#&(0+,* ,+,#$/"#$(, $"0'*) +0/ 1# '+)#-/,Z#+ '+/(* ,/ *#,$/ J7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
83/170Y !
V#E'(-#$ ,+/#+,/,* 4-04"9*,X($ ;(/"
RO[M
" :+0X,4,-(+ > .&BZ& ),(*9 !0-
" !(+g,4,-(+ a== '+(/$ ),(*9 !
D(2 L[ fc=Z&5 /0 )0$# ,/
@a '+(/$BZ& ),(*9J
5X 4K78=:7 G89O BK@7;G9 `9== >=F;Ra
" S9* &'! 0-" &O T1# )(=1CC0( 19C$ E$+;1C) .&BZ& ),(*9 !0-
" !(+g,4,-(+ a== '+(/$ ),(*9 !
D(2 L[ fc=Z&5 /0 )0$# ,/
@a '+(/$BZ& ),(*9J
#X +89O BK@7;G9 %K:KC=L=:7
YX *:7=GL=E8K7= G89O +=@;LL=:EK78;:9
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
84/170Y?
8+9 < 0- *#$$ D+0/ ,).(//#) (+/0"0$4(/,*JA
" 8 f?a 9#,-$!
" P1#$(/9 LOS f?= !
".)%1C* &' !
"I.0Z#- !
"H-0$$ 6,-(30$# 6#(+$ !
"F'--#+/ $9$/#.(3 (+2#3/(0+ !
"S..01(*(/9 #7&7 4,-,4*#&(,5
*0+&]",'* /-,6#* f^ "0'-$ !
"G-#]#3*,.4$(, !
"U#"9)-,/(0+B "94#-#.#$($B
PMII!
"O'*/(4*# 4-#&+,+39 !
"8$$($/#) -#4-0)'3/(6#
/-#,/.#+/ !
O01(*($,/(0+
860() )#"9)-,/(0+
4K78=:7 G89O BK@7;G9 %K:KC=L=:7
ZX 2;R G89O +=@;LL=:EK78;:9
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
85/170Y^
cX^XY 4;97:K7KF G89O K99=99L=:78** ;0.#+ $"0'*) 1# ,$$#$$#) ,2/#- )#*(6#-9 ,+) $/-,/(2(#) (+/0 -($Z &-0'4$,330-)(+& /0 -($Z 2,3/0-$ ,+) 022#-#) /"-0.104-04"9*,X($ ;(/" RO[M ;"#-#,44-04-(,/# D!,1*# Y7d7=F;Ra
&< -($Z 2,3/0-$ !
8+9 0+#" F,#$,-#,+ $#3/(0+ (+ *,10'- !" LOS f^= !
" G-0*0+) "0$4(/,*,).($$(0+!
" O#)(3,* 30.0-1()(/(#$ #7&7 ! M#,-/B*'+& )($#,$# !
IR:! F,+3#-! S+2*,..,/0-9 30+)(/(0+$! C#4"-0/(3 $9+)-0.#! I(3Z*# 3#** )($#,$# !
!",*,$$,#.(,! SKUT!
8/ *#,$/ @ ),9$ 40$/+,/,*4-04"9*,3/(3 RO[M
S2 4#-$($/(+& 0- f? -($Z 2,3/0-$530+$()#- #X/#+)(+&/"-0.104-04"9*,X($ ;(/" RO[M
#X +89O BK@7;G9 %K:KC=L=:7
"K>F= cX^XYH +89O CG;DV9 K:E 8:E8@K78;:9 B;G V;97:K7KF
7;VG;V
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
86/170Ya
cXb %#/$%$&" () 4+$/&" -(%$& -*". ".$#&"*4.(!4.(2*4*1 #&"*5(1P !P&1+(%$
[0.#+ ;(/" 8GRI 02 3"(*)1#,-(+& , ,*-#,)9 0+ #$/,1*($"#) ,+/(30,&'*,/(0+ ;"0,-# 30+/#.4*,/(+& , 4-#&+,+39 $"0'*) 1# 30..#+3#) 0+ ,$4(-(+ ,+) 1# $;(/3"#)
2-0. ;,-2,-(+ /0 /"#-,4#'/(3 )0$# RO[M '40+ 30+2(-.,/(0+ 02 4-#&+,+395 ;"(3"$"0'*) 1# 30+/(+'#) '+/(* )#*(6#-95 ,/ ;"(3" 40(+/ /"#9 .,9 -#30..#+3#;,-2,-(+7?
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
87/170Yd
+=@;LL=:EK78;:9 B;G %K:KC=L=:7 ;B 4G=C:K:7 -;L=:
R87< #42!
/GKE=
"K>F= cXbH %K:KC8:C #42! 8: VG=C:K:@M
F
F
F
F
F
[0.#+ ;(/" 8GRI 02 3"(*)1#,-(+& , ,*-#,)9 0+ #$/,1*($"#)
,+/(30,&'*,/(0+ ;"0 ,-# 30+/#.4*,/(+& , 4-#&+,+39 $"0'*) 1#30..#+3#) 0+ ,$4(-(+
[0.#+ ;(/" 8GRI ,*-#,)9 0+ #$/,1*($"#) ,+/(30,&'*,/(0+ $"0'*) 1#$;(/3"#) 2-0. ;,-2,-(+ /0 /"#-,4#'/(3 )0$# RO[M '40+ 30+2(-.,/(0+02 4-#&+,+39 4*'$ ,$4(-(+
[0.#+ ;(/" 8GRI 0+ #$/,1*($"#) ,+/(30,&'*,/(0+ $"0'*) 30+/(+'#/"#-,4#'/(3 RO[M '+/(* )#*(6#-95 ,/ ;"(3" 40(+/ /"#9 .,9-#30..#+3# ;,-2,-(+
[0.#+ ;(/" -#3'--#+/ #,-*9 2#/,* *0$$ ,$ /"# 4-#)0.(+,+/.,+(2#$/,/(0+ 02 8GRI $"0'*) 1# 022#-#) ,$4(-(+ ,*0+# 0- ,$4(-(+ 4*'$4-04"9*,3/(3 )0$# TbM 0- RO[M 2-0. /"# /(.# 02 4-#&+,+3930+2(-.,/(0+ '+/(* )#*(6#-9
8$4(-(+ 4*'$ 4-04"9*,3/(3 )0$# TbM 0- RO[M($ 4-#2#--#) (+ ;0.#+;"0 ",6# 4-#)0.(+,+/*9 .,+(2#$/#) 4-#6(0'$ *,/# 4-#&+,+39 *0$$ 0-4*,3#+/,**9 .#)(,/#) 4-#&+,+39 .0-1()(/9 D4-#]#3*,.4$(, 0- STHVJ
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
88/170Y@
+=@;LL=:EK78;:9 /GKE=
L
!"# #*(.(+,/(0+ ",*2]*(2# 02 RO[M ($ (+3-#,$#) (+ -#+,* (+$'22(3(#+395
/"#-#20-# -#)'3(+& /"# )0$# /0 > .&BZ& 0+3# ),(*9 #+0X,4,-(+ ,+)
.0+(/0-(+& /"# /-0'&" ,+/(]k, 20- /0X(3(/9 ,+) 4#,Z ,+/(]k, /0 ,)_'$/
)0$, ($ +#3#$$,-9
L
!(+g,4,-(+ ($ $,2# /0 1# '$#) '4 /0 , F- F* 02 F= eXUH "G=K7L=:7 ;B ,"$ 8: 9V=@8KF V;VDFK78;:9
8+/(30,&'*,/(0+ (+ /"# #*)#-*9 ($ $(.(*,- /0 /"# +#-,* 404'*,/(0+ 1'/ (/
.'$/ 1# +0/#) /",/ /"#$# 4,/(#+/$ .,9 ",6# '+)#-*9(+& -#+,* (+$'22(3(#+39
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
89/170YY
eXY #&"*3(#/02#"*(& )(+ $!"#52*!.$1 ,"$ *& !"+(N$ 4#"*$&"!P+3# /"# )(,&+0$($ 02 UK! ",$ 1##+ 30+2(-.#) ;(/" 30.4-#$$(0+ )'4*#X U044*#-'*/-,$0'+)5 .0$/ 4,/(#+/$ ;(/" 6#+0'$ /"-0.10#.10*($. ;(** -#$40+) /0,+/(30,&'*,/(0+7=987M
+=@;LL=:EK78;: /GKE=
!"# )'-,/(0+ 02 ,+/(30,&'*,/(0+ 20- #$/,1*($"#) K!: (+ $/-0Z#
4,/(#+/$ ($ ,/ *#,$/ ? .0+/"$ 1'/ .,9 1# #X/#+)#) (2 /"# -($Z 02
K!: -#3'--#+3# -#.,(+$ "(&"
F
"K>F= eXYH #:78@;KCDFK78;: ;B =97K>F89
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
90/170Yc
8+/(30,&'*,/(0+ 40$#$ , $(&+(2(3,+/ 3",**#+ (+ /"# 4,#)(,/-(3 404'*,/(0+7 !"#
-#$40+$#5 )($/-(1'/(0+5 1(+)(+& ,+) 3*#,-,+3# 02 ,+/(/"-0.10/(3$ ,-# ,])#4#+)#+/
;"(3" .,Z#$ )0$(+& ,+) .0+(/0-(+& )(22(3'*/7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
91/170c=
!"'$ /"#-# ($ '+3#-/,(+/9 06#- "0; 1#$/ /0 .0+(/0- '+2-,3/(0+,/#) "#4,-(+ /"#-,49
(+ 3"(*)-#+5 &(6#+ /"# +0+]'+(20-.(/9 ,+) *,3Z 02 3,*(1-,/(0+ 02 (+$/(/'/(0+,* 8G!!
6,*'#$ /0 0/"#- .#,$'-#$ 02 "#4,-(+ ,3/(6(/9 $'3" ,$ ,+/(]k, ,3/(6(/9 0- 4-0/,.(+#
+#'/-,*($,/(0+ ,+) /"# *,3Z 02 -#,)9 ,6,(*,1(*(/9 02 /"# ,*/#-+,/(6# ,$$,9$7?= ^ "
cd ] >= ^ "
f>a ^ "
"K>F= eXZXUH 4G;7;@;F B;G 8:7GKA=:;D9 D:BGK@78;:K7=E
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
92/170E?
F5,3, &% '* 6"-" -* 6,.&', *G-&0"# G3*G5$#"+-&+ 6*%,% *. CH/> F5, ,..&+"+$ *. I%&'1
" 6*%, *. ?J I'&-%8K1 G,3 5*I3 "% " +*'-&'I*I% &'.I%&*' 5"% '*- L,,' G3*M,'>
@ABACAB /581 1::1D4< 6: -EF
N#,,6&'1 &% " K'*O' %&6, ,..,+- *. &'-3"M,'*I% CH/ O&-5 0"P*3 L#,,6&'1 3"-,% "%
5&15 "% ;=Q &' *', %-I6$ &' G",6&"-3&+ RSC G"-&,'-% O5* 3,+,&M,6 CH/ -5,3"G$> 4+*00*' +"I%, *. ."-"# L#,,6&'1 &% "++&6,'-"# 5,G"3&' *M,36*%, "% " 3,%I#- *. 63I1
,33*3T O&-5 UJJJ I'&-%80V M&"#% L,&'1 0&%-"K,'#$ %,#,+-,6 &'%-,"6 *. UJ I'&-%80V
M&"#%>;;;
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
93/170E;
%KLF (I1 &35457? 401749134861> %+5,6I#,6 #I0L"3 GI'+-I3, "'6 &'-3"W-5,+"#-5,3"G$ *' H3&6"$d *0&- F5I3%6"$ ,M,'&'1 6*%, "'6 H3&6"$ 0*3'&'1 6*%,D>
@ABAGAO /47>5?54M 6: 01D63EQ %"#&', -* +3,"-, " ;J 0180V %*#I-&*'T .3*0 O5&+5 %-*+K J>@ 0V 0"$ L,&'P,+-,6 %IL+I-"',*I%#$ -O&+, 6"$T ,'"L#&'1 *G-&0I0 I%, *. -5, G3,W.#,6 %$3&'1,
W6&%G,'%,6 M*#I0,%>
@ABAB F1J7053 01210
?> 9#"%0" #,M,#% *. M&-"0&' :W6,G,'6,'- ."+-*3% "3, G5$%&*#*1&+"##$ 6,+3,"%,6 &'',OL*3'% -* #,M,#% -5"- "3, +*0G"3"L#, -* "6I#-% 3,+,&M&'1 O"3."3&' O&-5 R2e *.
;>J -* @>J;> R'."'- .*30I#" &% %IGG#,0,'-,6 O&-5 M&-"0&' : -* G3,M,'- 5",0*335"1&+ 6&%,"%,
*. -5, ',OL*3'@> ["3."3&' &% *'#$ "M""L#, &' -"L#,- .*30=> ["3."3&' 3,]I&3,% .3,]I,'- 0*'&-*3&'1U> 93*L#,0% O&-5 M"%+I#"3 "++,%%
["3."3&' &% -5, 0*%- +*00*'#$ I%,6 *3"# "'-&+*"1I#"'-> F5, -5,3"G,I-&+ 3"'1,% "3,6&3,+-#$ ,X-3"G*#"-,6 .3*0 "6I#- G"-&,'-%>;
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
94/170E@
@ABAP "=069>6?M )I++,%% 3"-,% .*3 -53*0L*#$%&% &' G",6&"-3&+
G"-&,'-% M"3$ L,-O,,' F&%%I, G#"%0&'*1,' "+-&M"-*3 &% -5, "1,'- *.
+5*&+, L,+"I%, *. ,XG,3&0,'-"# ,M&6,'+, *. &0G3*M,6 +#*- #$%&%T .&L3&' %G,+&.&+&-$
"'6 #*O &00I'*1,'&+&-$ O5,' +*0G"3,6 O&-5 %-3,G-*K&'"%, *3 I3*K&'"%,>
@ABAPAC "=069>6?M?11853I
! L#,,6&'1 A%I+5 "% **b&'1 .3*0 O*I'6D +"' L, -3,"-,6 L$ #*+"# G3,%%I3, "'6
%IGG*3-&M, +"3,> !"P*3 L#,,6&'1 0"$ L, -3,"-,6 L$ %-*GG&'1 -53*0L*#$-&+ -5,3"G$
"'6 "60&'&%-,3&'1 +3$*G3,+&G&-"-, A? I'&-8U K1 *3 U -* ?J 0V8K1 6*%,D "'6 "'
"'-&.&L3&'*#$-&+ *3 L*-5>;1D469M
)I31&+"# -53*0L,+-*0$ &% 3"3,#$ I%,6 &' +5?,' "'6 &% 3,%-3&+-,6 -* -5, .*##*O&'1
%&-I"-&*'% AF"L#, E>@>; N,.*3, -53*0L*#$%&% &% I%,6T +*'+I33,'- 5",0*%-"-&+ G3*L#,0% %I+5 "%
-53*0L*+$-*G,'&" "'6 M&-"0&' : 6,.&+&,'+$ %5*I#6 L, +*33,+-,6
;> 93,W-5,3"G$ G#"%0&'*1,' 3,G#,'&%50,'- -53*I15 .3,%5 .3*b,' G#"%0"
A?JW?U 0V8K1D &% 1&M,'
@> CH/ &% 3,6I+,6 -* ?J I'&-%8K185*I3 -53*I15*I- -5, 6I3"-&*' *. -94-5,3"G$ "'6 3,%I0,6 "- G3,M&*I% -5,3"G,I-&+ 6*%, %IL%,]I,'-#$
=> -W94 "- J>U 018K185*I3 &'.I%,6 *M,3 < 5*I3
"7>?1 @ABAPS "=069>6?M45D 4=107JM H54= 4*(GQT
?> RYS -53*0L*%&% &' "%%*+&"-&*' O&-5 &'-3"M"%+I#"3 ,X-,'%&*' *. [%g
-I0*I3;> 4+I-, -53*0L*%&% *. N#"#*+KWF"I%%&1 %5I'-@> V&.,W-53,"-,'&'1 &'-3"+"36&"+ -53*0L*%&% &00,6&"-,#$ ".-,3 +*0G#,X
+"36&"+ %I31,3$=> 93*%-5,-&+ M"#M, -53*0L*%&%U> ),G-&+ -53*0L*%&% 9,3&G5,3"# "3-,3$ -53*0L*%&% %,+*'6"3$ -* M"%+I#"3 "++,%% &'
',*'"-,%
"7>?1 @ABAQS &385D74563< :60 1D469M 53 D=5?8013GQT
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
95/170E=
+1D69913874563< ,0781
"7>?1 @ABARS (3454=069>645D "=107JM 738 *012134563 6: "=069>666
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
96/170EU
S
%59>X4=01741353I 60 60I73X4=01741353I 7D;41 :19607? 70410M 4=069>6U I'&-%80V "- ? 0V85
*105J=107? 7041057? D74=1410X01?7418 "#
R00,6&"-, 3,0*M"# *. +"-5,-,3
CH/ *3 V![/ O&-5 *3 O&-5*I- -53*0L*#$%&% *3 %I31&+"#
-53*0L,+-*0$
'163741< H54= -($
93*G5$#"X&% O&-5 #*OW6*%, CH/ &'.I%&*' M&" C4S A5,G"3&'
+*'+,'-3"-&*' J>;UW? I'&-80VT -*-"# 5,G"3&' 6*%, *. ;UW;JJ
I'&-%8K186"$D -* 0"&'-"&' G"-,'+$
$70857D D74=14105Y74563 257 73 70410M
RY CH/ A?JJ I'&-%8K1 L*#I%D "% -53*0L*G3*G5$#"X&% *3 "%G&3&'
$101>07? 6
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
97/170E@;fCG -* @?Q *. -53*0L*,0L*#&+ ,M,'-% *++I33,6 ,M,'
&' O*0,' O5* 6&6 '*- 1,- G3,1'"'->;?1 @AOAGACS $?7
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
99/170Ef
@AOAGACAG .57I366
R' G"-&,'-% O5* 6,M,#*G I'I%I"# %$0G-*0% A',I3*#*1&+"# %$0G-*0% *3 ',+KG"&'D .*##*O&'1 4eFT "'6 ,%G,+&"##$ &' -5*%, O5* 6,M,#*G 7/))T -5, G3,%,'+,*. "3-,3&"# "'6 M,'*I% -53*0L*-&+ ,M,'-% %5*I#6 L, +*'%&6,3,6 "'6 "GG3*G3&"-,&'M,%-&1"-&*'% +"33&,6 *I->
@AOAGACAB "01749134 6: 4=069>6
4## G"-&,'-% O5* 6,M,#*G M,'*I% -53*0L*%&% %5*I#6 L, 0*'&-*3,6 +#*%,#$ "%"GG3*X&0"-,#$ ?JQ *. -5,%, G"-&,'-% 0"$ 6,M,#*G G3*13,%%&*' *. -53*0L&T O&-5&'6"$%T ,M,' ".-,3 -5,$ 5"M, L,,' &'&-&"-,6 *' -5,3"G,I-&+ +*"1I#"-&*'>;6J06J=M?7U5< 53 ]F//
F5,3, &% '* ,M&6,'+, -* 3,+*00,'6 3*I-&', I%, *. -53*0L*G3*G5$#"X&% &' "##G"-&,'-% I'6,31*&'1 RYH> R' G"-&,'-% O5* 6,M,#*G 0*6,3"-, -* %,M,3, 7/))T
-53*0L*G3*G5$#"X&% %5*I#6 L, &'&-&"-,6> S*'%&6,3"-&*' %5*I#6 L, 1&M,' -*+*'-&'I, -53*0L*G3*G5$#"X&% .*3 " 0&'&0I0 *. = O,,K% L,$*'6 -5, 3,%*#I-&*' *.%$0G-*0"-&+ 7/)) &. -5, +$+#, &% I'%I++,%%.I# "'6 G*%%&L#$ .*3 IG -* ?@ O,,K%6I3"-&*' &. -5, G"-&,'- +*'+,&M,%> R- &% 3,+*00,'6,6 -5"- -5&% *G-&*' &% 6&%+I%%,6O&-5 -5, G"-&,'- -"K&'1 &'-* +*'%&6,3"-&*' -5"- O5, -5, "+-I"# 3&%K *. -53*0L*%&%&% %0"##T -5, +*'%,]I,'+,% 0"$ L, %&1'&.&+"'- "'6 -5, I%, *. -53*0L*G3*5$#"X&%5"% +*%- &0G#&+"-&*'%>
+1D69913874563< ,0781
S
N
S
"7>?1 @AOABS "=069>6J06J=M?7U5< 738 401749134 6: !"# :6??6H53I (+"
F53*0L*G3*G5$#"X&% %5*I#6 L, &'&-&"-,6 R' G"-&,'-% O5* 6,M,#*G0*6,3"-, -* %,M,3, 7/))
F53*0L*G3*G5$#"X&% %5*I#6 L, +*'-&'I,6 .*3 " 0&'&0I0 *. = O,,K%L,$*'6 -5, 3,%*#I-&*' *. %$0G-*0"-&+ 7/)) &. -5, +$+#, &%I'%I++,%%.I# "'6 G*%%&L#$ .*3 IG -* ?@ O,,K% 6I3"-&*' &. -5, G"-&,'-+*'+,&M,% A*G-&*' 6&%+I%%,6 O&-5 G"-&,'-D
9"-&,'-% O5* 6,M,#*G M,'*I% -53*0L*%&% .*##*O&'1 4eF %5*I#6 L,-3,"-,6 O&-5 -5,3"G,I-&+ V![/ -53*I15*I- G3,1'"'+$ "'6 .*3 IG -*%&X O,,K% G*%-G"3-I0
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
100/170EE
@AP F]+K]'(% $]'"+($#*"&]' ('. !"#
@APAC &34068;D4563
S*0L&',6 5*30*'"# +*'-3"+,G-&*' &'+#I6,% -5, +*0L&',6 *3"# +*'-3"+,G-&M, G#%
AS7SDT -5, +*0L&',6 5*30*'"# G"-+5T -5, +*0L&',6 5*30*'"# 3&'1 "'6 -5,
+*0L&',6 &'P,+-"L#, M"3&,-$> F5, S7S &% L$ ."3 -5, 0*%- +*00*'#$ I-&%,6 .*30 *.
+*0L&',6 5*30*'"# +*'-3"+,G-&*' "'6 -5,3,.*3, 0*%- 6"-" 3,1"36&'1 -5, I%, *.+*0L&',6 +*'-3"+,G-&M,% "3, ,X-3"G*#"-,6 .3*0 ,M&6,'+, .3*0 S7S I%,> R'
"66&-&*' -* +*0L&',6 5*30*'"# +*'-3"+,G-&*'T +,3-"&' *G-&*'% 0"$ +*'-"&' *'#$ "
G3*1,%-*1,' "'6 &% I%,6 ,&-5,3 *3"##$T "' &'P,+-"L#, *3 "% "' &0G#"'->; F5, 3&%K *. YF^ "0*'1%-
S7S I%,3% &% "GG3*X&0"-,#$ -O&+, -5"- *. '*'WI%,3% AE -* ?J8?JTJJJ O*0"'W$,"3%j "M,3"1, "+3*%% "## L3"'6% %-I6&,6D>;c=
F5, 3&%K *. YF^ &% 13,"-,%- &' -5, .&3%- .,O 0*'-5% *. %-"3-&'1 S7ST ".-,3 O5&+5 -5,
3&%K ."##% "#-5*I15 &% %-# 5&15,3 -5"' "0*'1 '*'WI%,3% I'- S7S &% %-*GG,6>;cJW;c=
F5, 3&%K 3,-I3'% -* #,M,#% -5"- *. '*'WI%,3% O&-5&' O,,K% *. 6&%+*'-&'I"-&*'>;c=
N*-5 -5, ,%-3*1,' "'6 G3*1,%-*1,' +*'-,'- *. -5, +*0L&',6 *3"# +*'-3"+,G-&M,
G# 5"M, L,,' &0G#&+"-,6 &' 6&..,3,'+,% &' M,'*I% -53*0L*-&+ 3&%K L,-O,,'G3*6I+-%> /*O,M,3T ,M,' &. -5,%, 3&%K% "3, 3,"#T -5, "L%*#I-, 6&..,3,'+, &' 3&%K
L,-O,,' G3*6I+-% &% %0"##T L,+"I%, -5, L"+K13*I'6 &'+&6,'+, *. M,'*I%
-53*0L*,0L*#&%0 &' $*I'1 O*0,' &% ,%%,'-&"##$ #*O>;c=
SI33,'- I%, *. 63*%G&3,'*', *3 +$G3*-,3*', *3"# +*0L&',6 +*'-3"+,G-&M,%
&'+3,"%,% -5, 3&%K *. YF^ +*0G"3,6 O&-5 %,+*'6 1,',3"-&*' G#%> R' -5, +*'-,X- *.
+*'-3"+,G-&M, I%,T '*'W*3"# 3*I-, *. ,-5&'$#W,%-3"6&*# "60&'&%-3"-&*' %,,0% -* L,
0*3, -53*0L*1,'&+ -5"' *3"# 3*I-,>;c=
Y,'*I% -53*0L*,0L*#&%0 "GG,"3% -* L, 5&15,3 &' *M,3O,&15- I%,3% O5, -5,
"%%*+&"-&*' O&-5 %0*K&'1 &% %-# +*'-3*M,3%&"# A%0*K&'1 &'+3,"%,% -5, 3&%K *.
"3-,3&"# -53*0L*%&% L$ ; -* = .*#6D>@@?R- &% 3,+*00,'6,6 -5"- .*3 O*0,' O&-5 " L*6$
0"%% &'6,X *. @U K180;*3 13,"-,3T -5, 3&%K% *. S/S 0"$ *I-O,&15 -5, L,',.&-%>
H*3 O*0,' "1,6 *M,3 @U $,"3% O5* "3, +I33,'- %0*K,3% *3 O5* 5"M, %-*GG,6
%0*K&'1 #,%% -5"' ? $,"3 "1*T -5, I%, *. S/S &% '*- 3,+*00,'6,6>@@;
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
101/170?JJ
@APAB K185D7? #?5I5>5?54M $0541057 :60 $63407D1J4521 -
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
102/170?J?
Z!94
2^FW^F
V2B8 FB
R!9V42F)
V2B
RCZ
S7S 979
= ; ;; ;
= @ @@ @
= ; ;; ;
= ; ;; ;
; ? ?? ?
? ? ?? ?
= ; ;; ;
? ? ?? ?
; ? ?? ?
@ ? ?? ?
; ? ?? ?
K185D7? #?5I5>5?54M $0541057 :60 D69963 =609637? D63407D1J4521 9"-&,'-%
O&-5 +"'+,3 6&"1'*%,6 "- -5, %"0, -&0, *. "+I-, YF^ 5"M, " 13,"-,3 #&K,#&5**6 *.
6&%-"'- 0,-"%-"%,% "'6 #*O,3 %I3M&M"# 3"-,%> F5, "+-&M"-,6 +*"1I#"-&*' +"%+"6,
"%%*+&"-,6 O&-5 YF^ &% -5*I15- -* G3*0*-, "'1&*1,',%&% "'6 0,-"%-"%,%> F5,3, &%
'*O ,M&6,'+, -* %I11,%- -5"- V![/ -3,"-0,'- +*I#6 6,#"$ 0,-"%-"%,% &' 6&..,3,'-
-I0*I3% "'6 &0G3*M, %I3M&M"#>;f?T;f;T;f=
@AQAG *74=6J=M6
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
104/170?J@
@AQAB K737I19134 6: !"# 53 D73D106J06J=M?7U5 9*%-W*G,3"-&M,#$T ,X-,'6,6 6I3"-&*' *. V![/ A.3*0 c -* ;f
6"$% ".-,3 %I31,3$D 5"% L,,' %5*O' -* %&1'&.&+"'-#$ 3,6I+, -5, &'+&6,'+, *.
ZYF>;cc S*'%,]I,'-#$T -53*0L*G3*G5$#"X&% O&-5 ,X-,'6,6 6I3"-&*' V![/
%5*I#6 L, +*'%&6,3,6 &' "## G"-&,'-% I'6,31*&'1 %I31,3$ .*3 1$'",+*#*1&+"#
0"#&1'"'+$>;f;f@F&'b"G"3&' 5"% L,,' %5*O' -* L, ,..,+-&M,O&-5 " *'+, 6"$ 6*%&'1>;EJ F5,3, &% '* 6&3,+- ,M&6,'+, -5"- 3&M"3*X"L"' &%
%IG,3&*3 -* V![/ &' G"-&,'-% O&-5 +"'+,3 LI- 0"$ L, "' "#-,3'"-&M, ,%G,+&"##$ &'
G"-&,'-% O5* 6,+#&', 3,1I#"3 &'P,+-&*'% O&-5 V![/>?
N
+1D69913874563< ,0781
4
4
"7>?1 @AQAOS *012134563 738 "01749134 6: !"# 53 $73D101>
"'-&WG5*%G5*#&G&6 %$'63*0, *3 +"'+,3DT -5, 3&%K *. 3,+I33,'+, &% %&1'&.&+"'-#$ #,%%
-5"' #*O,3 #&0L ZYF A;Q M>%> ?EQ "- U $,"3%D>;EU 93*#*'1,6 "'-&+*"1I#"-&*'
L,$*'6 @ 0*'-5% &% 1,',3"##$ '*- &'6&+"-,6 .*3 IGG,3 #&0L ZYF>;EU
@ARAB $101>07? !153 "=069>6;E;Ec
V*'1W-,30 +*5*3- .*##*OWIG %-I6&,% &'6&+"-, -5"- 3,+I33,'- +,3,L3"# M,&'
-53*0L*%&% &% I'+*00*' G,35"G% L,+"I%, 0"'$ &'&-&"# ,M,'-% *++I3 &' $*I'1
G"-&,'-% O&-5 -,0G*3"3$ G3,+&G&-"-&'1 ."+-*3% A,>1> 5$G,3,0,%&% 13"M&6"3I0D>;E;T;E@
HI3-5,30*3,T -5, G3,%,'+, *. 5,3&-"L#, -53*0L*G5&" 6*,% '*- &'.#I,'+, -5,
3,+I33,'+, 3&%K> F5,3,.*3,T #*'1W-,30 "'-&+*"1I#"-&*' %5*I#6 '*- L, ',+,%%"3$ &'
0*%- G"-&,'-%>;Ec
@ARAO /J?73D=35D !153 "=069>6;E
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
106/170?JU
F5, G3,%,'+, *. #&M,3 +&335*%&% "'68*3 G*3-"# 5$G,3-,'%&*' O&-5 *,%*G5"1,"#M"3&+,% "'6 5$G,3%G#,'&%0 O&-5 -53*0L*+$-*G,'&"T -5, %,]I,#", -* %G#"'+5'&+M,&' -53*0L*%&% .I3-5,3 &'+3,"%, -5, 3&%K *. L#,,6&'1 %5*I#6 "'-&+*"1I#"-&*' L,G3,%+3&L,6>;Ec
@ARAP &3D581347? 4=069>6
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
107/170?J
S#&'&+"# G5"30"+&%-% &'W+5"31,6 G3*M&6,6 G"-&,'- ,6I+"-&*'T 0*'&-*3,6 G"-&,'-%.*3 5,0*335"1&+ "'6 -53*0L*,0L*#&+ +*0G#&+"-&*'%T "'6 "6PI%-,6 O"3."3&'%*6&I0 6*%"1, -* 0"&'-"&' -5,3"G,I-&+ R2e>
c> F5&% 6*+I0,'- %,-% *I- %-"'6"36&%,6 1I&6,#&',% .*3 -5, *G,3"-&*' *. !F4SW[+#&'&+ &'+*3G*3"-&'1 !F4SW ["3."3&' 93*-*+*# GIL#&%5,6 L$ 95"30"+,I-&+"#),3M&+,% Z&M&%&*'T !7/ !"#"$%&">@J;
CTAG '("&]'(% ,-&.('$# ('. (..&"&]'(% +#/]-+$#/?> 93*-*+*#W!,6&+"-&*' F5,3"G$ 465,3,'+, S#&'&+\ ["3."3&'> 95"30"+,I-&+"#
),3M&+,% Z&M&%&*'T !&'&%-3$ *. /,"#-5 !"#"$%&"> H&3%- ^6&-&*' ;J?J>
;> BI&6,#&',% *' 73"# 4'-&+*"1I#"-&*'\ F5&36 ,6&-&*'> N3&-&%5 p*I3'"# *. /",0"-*#*1$@36 ,6&-&*' ?EEfd?J?T@c=W@fc
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
108/170?Jc
CTAB ]V_#$"&!#/?> F* G3*M&6, +*'-&'I&-$ "'6 ,'5"'+, G"-&,'- +"3, -53*I15 ,6I+"-&*'T 0*'&-*3&'1T
"'6 +#*%, .*##*OWIG -* G"-&,'-% O5* 3,]I&3, "'-&+*"1I#"-&*' -5,3"G$>
;> F* 0"X&0&b, -5, L,',.&-% *. "'-&-53*0L*-&+ -5,3"G$ "'6 0&'&0&b, -5, "6M,3%,,..,+- "'6 +*0G#&+"-&*'% 3,%I#-&'1 .3*0 "'-&-53*0L*-&+ -5,3"G$>
@> 4%%&%- G5$%&+&"'% &' -5, 0"'"1,0,'- *. G"-&,'- G3,%+3&L,6 O&-5 "'-&+*"1I#"'--5,3"G$>
=> ),3M, "% "' &'.*30"-&*' 3,%*I3+, .*3 G"-&,'-% "'6 ."0$8+"3, G3*M&6,3>
U> 93*M&6, +*'%I#-"-&M, "'6 ,6I+"-&*'"# %,3M&+,% -* G5$%&+&"'%T 6,'-&%-%T "'6 *-5,35,"#-5+"3, G3*M&6,3% *' "'-&-53*0L*-&+ 63I1 0"'"1,0,'- "'6 3,#"-,6 &%%I,%>
CTAO +#/*]'/&V&%&"/ ]E "F# $%&'&$(% *F(+K($&/" &'X$F(+,#BTG
?> ^'%I3, G"-&,'- 3,+,&M, ,6I+"-&*' 3,1"36&'1 O"3."3&' "- -5, &'&-&"# M&%&- "'63,&'.*3+, -5&% ,6I+"-&*' "- ,"+5 M&%&->
;> N, "O"3, *. -5, G*-,'-&"# ,..,+-% *. "66&-&*'"# -5,3"G$ A63I185,3L"#8%IGG#,0,'-8,#,+-&M, G3*+,6I3,D 1&M,' -* " G"-&,'- *' "'-&+*"1I#"'-%T "'6"33"'1&'1 ,"3#&,3 R2e -,%-&'1 "% 3,]I&3,6>
@> ^'%I3, G"-&,'- 3,+,&M, "GG3*G3&"-, R2e 0*'&-*3&'1 "'6 0"K, 6*%"1,3,+*00,'6"-&*' 1I&6,6 L$ -5, "GG3*M,6 G3*-*+*# A4GG,'6&X ?D
=> F3"'%+3&L, O"3."3&' G3,%+3&G-&*'%\"> F5&% "+-&M&-$ %5*I#6 L, 6*', L"%,6 *' -5, "13,,0,'- L$ -5, 5*%G&-"#
0"'"1,0,'- "'6 -5, 6*+-*3 &'W+5"31,> F5, 6*+-*3 0I%- L, "O"3, -5"- -5,.&'"# 3,%G*'%&L&-&,% .*3 -5, G3,%+3&G-&*' %5*I#6 L, #&"&%,6 O&-5 -5, 6*+-*3>93,%+3&G-&*' 5"% -* L, &'&-&"-,6 L$ -5, G5"30"+&%- "'6 +*I'-,3W%&1',6 L$ -5,6*+-*3>
L> 4+- G3*0G-#$ -* G"-&,'-% O&-5 L#,,6&'1 G3*L#,0% "'68*3 R2e a= *3 O5* "3,*-5,3O&%, +*'%&6,3,6 -* L, "- 3&%K *. L#,,6&'1>
U> F5, G"-&,'- %5"## L, 3,.,33,6 -* -5, G5$%&+&"' &' -5, .*##*O&'1 %&-I"-&*'%\"> 4+-I"# *3 %I%G,+-,6 %&1'% "'6 %$0G-*0% *. %,M,3, 5",0*335"1, 3,1"36#,%%
*. -5, R2e M"#I,>
L> 4+-I"# *3 %I%G,+-,6 %&1'% "'6 %$0G-*0% *. -53*0L*,0L*#&%0>
+> R2e M"#I,% *M,3 =>J *3 M"#I,% #,%% -5"' ?>J AR2e 3"'1, "- -5, 6&%+3,-&*' *. -5,3,%G,+-&M, 5*%G&-"#D
6> R2e `?>U .*3 G"-&,'-% O&-5 G3*%-5,-&+ M"#M, 3,G#"+,0,'->
,> [5,' -5, 6I3"-&*' *. -5,3"G$ 5"% L,,' +*0G#,-,6>
.> [5,' G"-&,'-% +*'%&%-,'-#$ 0&%% "GG*&'-0,'-% *3 3,0"&' '*'W+*0G#&"'- -*-5,3"G$>
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
109/170?Jf
^'%I3, +*33,+- 6&%G,'%&'1 *. O"3."3&' -"L#,-% &' -5, +#&'&+ -* -5, G"-&,'-%8+"3,
1&M,3%>
c> ^'%I3, "## G"-&,'-% 5"M, L,,' 1&M,' O"3."3&' L**K#,->
f> '%I3, "- -5, ,'6 *. -5, %,%%&*'T " %I00"3$ *. &0G*3-"'- &'.*30"-&*' &%
G3*M&6,6 -* -5, G"-&,'-% "'6 -5,&3 I'6,3%-"'6&'1 &% 3,"%%,%%,6>
CTAP K('*]L#+ +#`-&+#K#'" BTG
4- #,"%- *', G5"30"+&%- %5*I#6 L, G#"+,6 &' -5, +#&'&+> F5, G5"30"+&%- %5*I#6
%G,'6 "' "M,3"1, *. ?J -* ?U 0&'I-,% G,3 +"%, LI- #*'1,3 -&0, A"3*I'6 @J
0&'I-,%D O# L, ',,6,6 .*3 ',O#$ 3,.,33,6 +"%,%>
CTAQ (**]&'"K#'"
4## "GG*&'-0,'- O# L, %+5,6I#,6 L$ G5"30"+&%-% &'W+5"31, *. -5, +#&'&+>
CTAR L]+a *+]$#.-+#/F5, O*3K.#*O *. !F4S ["3."3&' &% "% %5*O' &' 4GG,'6&X ;>
CTAb *("'" /#%#$"&]'
?> 46I#- G"-&,'-% O5* "3, +I33,'-#$ *' O"3."3&' -5,3"G$ "% *I-WG"-&,'- .3*0 "'$
3,#,M"'- 6&%+&G#&',% A"% "13,,6 L$ -5, &'6&M&6I"# &'%-&-I-&*'D
;> 4## ',O +"%,% %5"## L, 3,.,33,6 L$ G5$%&+&"'% I%&'1 -5, %-"'6"36&%,6 3,.,33"#
.*30 A!F4Sq["3."3&'8H?\ 4GG,'6&X @D> H*3 G"-&,'- %-"3-,6 *' O"3."3&' -5,3"G$
&' -5, O"36T 3,.,33"#% %5*I#6 L, 0"6, G3&*3 -* -5, 6&%+5"31,>
@> 9"-&,'-% O5* "3, k%-"L#,g "'6 +*'%&6,3,6 "GG3*G3&"-, .*3 0"'"1,0,'- "- -5,
!F4SW["3."3&'>
=> S*0G#,X 5&15 3&%K G"-&,'-% ',,6 -* L, &6,'-&.&,6 "'6 "%%,%%,6 .*3 -5,
"GG3*G3&"-,',%% *. 0*'&-*3&'1 "- -5, !F4SW[> )*0, *. -5,%, +*'6&-&*'% 0"$
L, 3,.,33,6 L"+K -* -5, 6*+-*3\@J@
"> 4 K'*O' 5,3,6&-"3$ *3 "+]I&3,6 L#,,6&'1 6&%*36,3 AZ&%+I%% O&-5 S*'%I#-"'-
/",0"-*#*1&%-D
L> 4#+*5*#&+% 6I, -* &'%-"L&-$ &' "'-&+*"1I#"-&*' 0"'"1,0,'-
+> ),M,3, 0"#'*I3&%50,'- 6I, -* "L%*3G-&*' 6&..&+I#-&,%
6> !,'-"##$ # O&-5 '* +"3,3 %IGG*3- &' -5, +*00I'&-$
,> Z,0,'-&" O&-5 '* +"3,3 %IGG*3- &' -5, +*00I'&-$
.> V&M,3 ."I3,
1> ),M,3, 3,'"# &0G"&30,'-
5> Z*+I0,'-,6 ,M&6,'+, *. S2) 5",0*335"1,
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
110/170?JE
&> ),M,3, 5,"3- ."I3,
P> C'+*'-3*##,6 %,M,3, 5$G,3-,'%&*'
K> B"%-3&+W&'-,%-&'"# L#,,6&'1 &' -5, #"%- < 0*'-5%
#> 93,1'"'+$ AC31,'- 3,.,33"# -* "GG3*G3&"-, /",0"-*#*1&%-8S*'%I#-"'-7L%-,-3&+&"'D
0>F5*%, *' +5,0*-5,3"G$ .*3 0"#&1'"'- -I0*I3% A+*'%&6,3 V![/D
'> /*0*b$1*I% G3*-,&' S 6,.&+&,'+$ A5&15 3&%K *. %K&' ',+3*%&%D
CTA@ &'+ "#/"&',?> F5, 0,-5*6 .*3 R2e 0*'&-*3&'1 %5*I#6 L, 6,-,30&',6 L$ &'6&M&6I"# &'%-&-I-&*'
"'6 L#**6 %"0G#&'1 .*3 R2e 3,"6&'1 %5*I#6 L, G,3.*30,6 L$ -3"&',6 5,"#-5+"3,%-"..>
;> FO* 0,-5*6% "M""L#,\ 9*&'-W7.WS"3, AH&'1,3%-&+K8S*"1I+5,+K _eD *3#"L*3"-*3$ -,%-&'1>
@> R2e 3,%I#-% .3*0 ; 0,-5*6% "3, %"&6 -* L, &' 3,"%*'"L#, "13,,0,'- &. -5, -O*3,%I#-% "3, O&-5&' J>U R2e I'&-% *. ,"+5 *-5,3>@J=
=> S,3-"&' +*'6&-&*'% +"' &'-,3.,3, O&-5 -5, R2e -,%- ,>1> "'-&WG5*%G5*#&G&6
"'-&L*6$ %$'63*0, O5&+5 0"$ +"I%, -5, R2e -* L, ."#%,#$ 5&15>@J=T@JU
)I+5&'-,3.,3,'+, +"' O3*'1#$ %I11,%- G"-&,'- L,&'1 *M,3WO"3."3&'&%,6> 4#-,3'"-&M,#"L*3"-*3$ -,%- +"##,6 -5, +53*0*1,'&+ ."+-*3 _ #,M,#T O5&+5 &% " 0,"%I3, *.O"3."3&' ,..,+- -5"- &% '*- "#-,3,6 L$ -5, "'-&WG5*%G5*#&G&6 "'-&L*6&,% 0"$ *..,30*3, "++I3"-, -,%-&'1>
CTACT *("'" $]-'/#%%&',?> 9"-&,'- ,6I+"-&*' &% &0G,3"-&M, -* ,'%I3, %"., "'6 ,..,+-&M, I%, *. O"3."3&'
-5,3"G$> 4## ',O G"-&,'-% -* !F4SW[ %5*I#6 5"M, -5, O"3."3&' +*I'%,#&'1
+5,+K#&%- +*0G#,-,6 "'6 L,&'1 1&M,' " +*0G3,5,'%&M, O"3."3&' ,6I+"-&*'L"%,6 *' -5,&3 #,M,# *. I'6,3%-"'6&'1>
;> ^"+5 G"-&,'- %5*I#6 L, G3*M&6,6 O&-5 " !7/W"GG3*M,6 O"3."3&' L**K#,- "'68*3*-5,3 +*0G#&"'+, "&6%>
@> ^X&%-&'1 G"-&,'-% 0"$ L,',.&- .3*0 9^eR7ZRS ,6I+"-&*'"# ,..*3-% 3,&'.*3+&'1K,$ 0,6&+"-&*' %".,-$ &'.*30"-&*'T ,M,' ".-,3 &'&-&"# ,6I+"-&*' "'6 *'1*&'10*'&-*3&'1>@J R'+*3G*3"-&'1 G"-&,'- "',+6*-,% &'-* G5$%&+&"'WG"-&,'- 6&"#*1I,% *3 ,6I+"-&*'"#0"-,3&"#% 0"$ &'+3,"%, -5, ,..,+-&M,',%% *. -5, 0,%%"1,>@J
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
111/170??J
U> 9"-&,'- ,6I+"-&*' %5*I#6 &'+#I6, -5, .*##*O&'1\"> Z3I1 '"0,T %-3,'1-5 "'6 6,%+3&G-&*' *. -"L#,-
L> SI33,'- 6*%"1, "'6 "60&'&%-3"-&*' -&0,
+> e,"%*' .*3 -"K&'1 O"3."3&' "'6 5*O &- O*3K%
6> F5,3"G,I-&+ 1*"#% "'6 -5, "'-&+&G"-,6 #,'1-5 *. -3,"-0,'-
,> /*O -* 5"'6#, 0&%%,6 6*%,%
.> !,6&+"-&*'%8%IGG#,0,'-% "'6 6&,-"3$ &'-,3"+-&*'%
1> e,+*1'&-&*' *. %$0G-*0% *. L#,,6&'18-53*0L*%&%T "6M,3%, 3,"+-&*'% "'6 -5,"GG3*G3&"-, G3*+,6I3,% -* .*##*O
5> R0G*3-"'+, *. "65,3,'+, -* 63I1 3,1&0,' "'6 +#&'&+ "GG*&'-0,'-%
&> ^0G5"%&% *' -5, &0G*3-"'+, *. .*##*O IG "'6 6*+I0,'-"-&*'
P> [5"- -* 6* &. 6,'-"# -3,"-0,'-8%I31,3$ &% 3,]I&3,6
K> [5"- -* 6* &. %I31,3$ &% &'6&+"-,683,]I&3,6
#> 9"-&,'- ,6I+"-&*' *' -5, I%, *. O"3."3&' &' G3,1'"'+$ "'6 #"+-"-&*' A&.3,#"-,6D
0> [5* -* +*'-"+- 3,1"36&'1 "'$ O*33&,% *3 +*'+,3'% 3,#"-&'1 -* -5,&3 O"3."3&'
-5,3"G$>
9"-&,'- ,6I+"-&*' +5,+K#&%- &% G3*M&6,6 &' 4GG,'6&X =>
CTACC K]'&"]+&', ('. #!(%-("&]'?> 9"-&,'-g% 3,%G*'%, -* O"3."3&' -5,3"G$ %5*I#6 L, ,M"#I"-,6 L"%,6 *' R2e
3,%I#-% "'6 &'.*30"-&*' 1"-5,3,6 .3*0 G"-&,'-g% &'-,3M&,O>
;> FO* 6*+I0,'-% "3, I%,6\ H&3%- Y&%&- H*30 A!F4Sq["3."3&'8H;\ 4GG,'6&X UD *3H*##*OWCG Y&%&- H*30 A!F4Sq["3."3&'8H@\ 4GG,'6&X
@> F5, .*##*O&'1 +3&-,3&" %5*I#6 L, "%%,%%,6 -* +5,+K8,M"#I"-, G"-&,'-g% 3,%G*'%,-* O"3."3&' -5,3"G$ "'6 6,-,+- "'$ G*-,'-&"# G3*L#,0% G3&*3 -* 6*%"1,"6PI%-0,'-%\"> )&1'% "'6 %$0G-*0% *. 5",0*335"1, "'6 -53*0L*,0L*#&%0
L> S5"'1, &' +*'6&-&*'A%D 3,]I&3&'1 O"3."3&' -5,3"G$
+> e,+,'- "#-,3"-&*'% &' 6&,-T0,6&+"-&*'%T -*L"++* *3 "#+*5*# &'-"K,
6> 4#-,3"-&*'% &' *-5,3 0,6&+"# G3*L#,0% *3 3,+,'- #',%%,%
,> 465,3,'+, -* O"3."3&' -5,3"G$
.> 9"-&,'- I'6,31*&'1 %I31&+"# *3 6,'-"# G3*+,6I3,%
-
8/13/2019 CPG 2013- Prevention and Treatment of Venous Thromboembolism
112/170???
CTACG .]/(,# (._-/"K#'"?> !"3K,6 &'6&M&6I"# &'-,3WM"3&"L&-$ ,X&%-% .*3 -5, 0,-"L*#&%0 *. O"3."3&'> 9"-&,'-g%
1,',-&+ 0"K, IGT 6&%,"%, %-"-,% "'6 *-5,3 +*'+I33,'- 0,6&+"-&*'% "#%* "..,+-
-5, 3,%G*'%, *. O"3."3&' &' 6&..,3,'- G"-&,'-> F5,3,.*3,T -5, 3,%G*'%, &'
&'6&M&6I"# +"''*- L, 3,#&"L#$ G3,6&+-,6>
;> F5, O"3."3&' 6*%, %5*I#6 L, %,#,+-,6 -* 0"&'-"&' R2e O&-5&' -5, 3"'1,"++*36&'1 -* +I33,'- 1I&6,#&',% ,%-"L#&%5,6 L$ -5, 40,3&+"' S*##,1, *. S5,%-
Z*+-*3% S*'%,'%I% S*'.,3,'+, *' 4'-&-53*0L*-&+ F5,3"G$ A4SS9 ;J?;D>
@> Z*%"1, "6PI%-0,'-% %5*I#6 L, 1I&6,6 L$ +#&'&+"##$ "GG3*M,6 G3*-*+*# "'6
&